API
Navigational tip: click on "leads to" or the ID column to navigate to the KE Relationship.

KE Relationships

Id Upstream Event Relationship Type Downstream Event
1330 Binding, topoisomerase II leads to MLL translocation
1635 DSB leads to MLL translocation
305 TH synthesis, Decreased leads to T4 in serum, Decreased
366 Thyroperoxidase, Inhibition leads to T4 in serum, Decreased
443 Thyroidal Iodide, Decreased leads to T4 in serum, Decreased
2232 Inhibition, Na+/I- symporter (NIS) leads to T4 in serum, Decreased
2236 Increase, Biliary excretion TH glucuronide leads to T4 in serum, Decreased
2237 Increased, Hepatic thyroid hormone uptake/transport leads to T4 in serum, Decreased
2270 Increased, Clearance of thyroxine from serum leads to T4 in serum, Decreased
2423 Increased, T4/T3 catabolism leads to T4 in serum, Decreased
2476 Inhibition, Iodotyrosine deiodinase (IYD) leads to T4 in serum, Decreased
2483 Induction, Upregulation of glucuronyltransferase activity leads to T4 in serum, Decreased
1493 CYP7B activity, inhibition leads to 7α-hydroxypregnenolone synthesis in the brain, decreased
348 BDNF, Reduced leads to Aberrant, Dendritic morphology
568 Increased, Appetite and hunger leads to Abnormal, Foraging activity and behavior
575 Increased, Viral susceptibility leads to Abnormal, Foraging activity and behavior
583 Impairment, Learning and memory leads to Abnormal, Foraging activity and behavior
1147 Activation, Nicotinic acetylcholine receptor leads to Abnormal, Foraging activity and behavior
1157 Increased, Energetic demands and therefore metabolic stress leads to Abnormal, Foraging activity and behavior
2530 Decrease, Glucose uptake leads to Abnormal, Glucose homeostasis
329 Insufficiency, Vascular leads to Abnormal, Morphogenesis
2407 reduced production, VEGF leads to abnormal, placental labyrinth vasculature morphology
1150 Abnormal, Foraging activity and behavior leads to Abnormal, Role change within caste
564 Impairment, Learning and memory leads to Abnormal, Roll change within caste
578 Reduced, Antiseptic incorporated in food leads to Abnormal, Roll change within caste
1148 Abnormal, Foraging activity and behavior leads to Abnormal, Roll change within caste
1842 Distribution of chemicals leads to Absorption of photon energy
662 Accumulation, Damaged mitochondrial DNA leads to Accelerated, Aging
1864 Inhibition of N-linked glycosylation leads to Accumulation, misfolded proteins
295 Activation, Stellate cells leads to Accumulation, Collagen
303 Up Regulation, TGFbeta1 expression leads to Accumulation, Collagen
1628 Collagen Deposition leads to Accumulation, Collagen
1654 Differentiation of fibroblasts leads to Accumulation, Collagen
1655 EMT leads to Accumulation, Collagen
2138 Increase plasma Ang II leads to Accumulation, Collagen
2307 Increased proinflammatory mediators leads to Accumulation, Collagen
2594 Increased, Reactive oxygen species leads to Accumulation, Collagen
2652 Increased cellular proliferation and differentiation leads to Accumulation, Collagen
2502 Dysfunctional autophagy leads to Accumulation, Toxic Tau oligomers
661 Overwhelmed, Mitochondrial DNA repair mechanisms leads to Accumulation, Damaged mitochondrial DNA
190 Decreased, Mitochondrial fatty acid beta-oxidation leads to Accumulation, Fatty acid
475 Inhibition, Mitochondrial fatty acid beta-oxidation leads to Accumulation, Fatty acid
503 Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway) leads to Accumulation, Fatty acid
505 Increased, FA Influx leads to Accumulation, Fatty acid
508 Increased, LDL uptake leads to Accumulation, Fatty acid
512 Increased, De Novo FA synthesis leads to Accumulation, Fatty acid
1660 Decreased, Ketogenesis leads to Accumulation, Fatty acid
864 Oxidation, Uroporphyrinogen leads to Accumulation, Highly carboxylated porphyrins
1070 Inhibition, UROD leads to Accumulation, Highly carboxylated porphyrins
470 Inhibition, Mitochondrial fatty acid beta-oxidation leads to Accumulation, Liver lipid
471 Suppression, VLDL secretion leads to Accumulation, Liver lipid
474 Accumulation, Triglyceride leads to Accumulation, Liver lipid
502 Accumulation, Fatty acid leads to Accumulation, Liver lipid
110 Synthesis, De Novo FA leads to Accumulation, Triglyceride
132 Increase, FA Influx leads to Accumulation, Triglyceride
472 Accumulation, Fatty acid leads to Accumulation, Triglyceride
504 Increased, FA Influx leads to Accumulation, Triglyceride
1657 Up Regulation, SCD-1 leads to Accumulation, Triglyceride
2264 Decreased, Mitochondrial Fatty Acid Beta Oxidation leads to Accumulation, Triglyceride
2523 ADAM17 induction leads to ACE2 increased shedding
11 AchE Inhibition leads to ACh Synaptic Accumulation
459 ACh Synaptic Accumulation leads to AchE Inhibition
2031 Increased acinar cell exocrine secretion leads to Acinar cell proliferation
1441 Increase, intracellular calcium leads to Activate, calmodulin
1462 Increase, GABA leads to Activate, GABA-A receptor
1463 Increased, RDX dose leads to Activate, GABA-A receptor
1477 Increase, leukocyte adherence leads to Activate, leukocyte
1484 Increase, bicarbonate leads to Activate, mucosal defense
1485 Increase, mucous leads to Activate, mucosal defense
1486 Increase, mucosal blood flow leads to Activate, mucosal defense
1489 Increase, surfactant leads to Activate, mucosal defense
1438 Activation, 5-HT2A leads to Activate, PLC
1476 Activate, leukocyte leads to Activated, gastric ulcer formation
1533 Reduced, platelet aggregation leads to Activated, gastric ulcer formation
1536 Reduced, mucosal defense leads to Activated, gastric ulcer formation
1542 Decreased, angiogenesis leads to Activated, gastric ulcer formation
1545 Increased, leukocyte activation leads to Activated, gastric ulcer formation
1558 Reduced, SHP activity leads to Activated, LXR
1457 Activated, voltage-gated sodium channel leads to Activated, membrane depolarization
1554 Decreased, intracellular chloride leads to Activated, membrane depolarization
1453 Increased, glutamate leads to Activated, NMDA receptor
1455 Increased, intracellular sodium (Na+) leads to Activated, voltage-gated sodium channel
2704 Increased, Intracellular Calcium overload leads to Activation, calpain
2653 AchE Inhibition leads to Activation of Cyp2E1
2195 Mitochondrial dysfunction leads to ER stress
2641 Altered expression of NRF2 pathway-dependent genes leads to ER stress
1867 Apoptosis leads to Activation, hepatic stellate cells
2667 Non-coding RNA expression,alteration leads to Activation, inflammation pathway
1608 demethylation, PPARg promoter leads to Activation of specific nuclear receptors, PPAR-gamma activation
1610 activation of CEBPA leads to Activation of specific nuclear receptors, PPAR-gamma activation
248 Bile accumulation, Pathological condition leads to Activation of specific nuclear receptors, Transcriptional change
1353 Inactivation of PPARγ leads to Activation of TGF-β signaling
2595 Increase, DNA Damage leads to Activation of TP53
1374 Glutathione synthesis leads to Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene
1437 Decreased, extracellular serotonin leads to Activation, 5-HT2A
1531 Increased, extracellular serotonin leads to Activation, 5-HT2A
1392 Activation, mTORC2 leads to Activation, AKT
1418 Activation, PI3K leads to Activation, AKT
541 inflammation leads to Activation, AKT2
1420 Activation, PI3K leads to Activation, aPKC
1828 Inhibition, Nuclear factor kappa B (NF-kB) leads to Activation, Caspase 8 pathway
174 Activation, LXR leads to Activation, ChREBP
377 Covalent Binding, Protein leads to Activation, Dendritic Cells
378 Response, Keratinocytes leads to Activation, Dendritic Cells
834 Activation, Keratinocytes leads to Activation, Dendritic Cells
1699 Activation, Inflammatory cytokines, chemokines, cytoprotective gene pathways leads to Activation, Dendritic Cells
1700 N/A, Covalent binding to protein, possibly lysine residue leads to Activation, Dendritic Cells
2651 Increased proinflammatory mediators leads to Activation, Dendritic Cells
1102 prepubertal increase, Estrogen receptor (ER) activity leads to Activation, estrogen receptor alpha
175 Activation, LXR leads to Activation, FAS
1424 demethylation, PPARg promoter leads to Activation, FAS
1425 Activation, LRH-1 leads to Activation, FAS
1380 Activation, JNK leads to Activation, FOXO
1397 Activation, SREBP-1 leads to Activation, FXR
1406 Activation, NRF2 leads to Activation, FXR
1450 Increase, cortisone leads to Activation, Glucocorticoid Receptor
1364 Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK leads to Activation, HIF-1
1396 Activation, mTORC1 leads to Activation, HSD17B4
1410 Activation, PPARα leads to Activation, HSD17B4
88 N/A, Covalent binding to protein, possibly lysine residue leads to Activation, Inflammatory cytokines, chemokines, cytoprotective gene pathways
2202 Covalent Binding, Protein leads to Activation, Inflammatory cytokines, chemokines, cytoprotective gene pathways
1390 Increase, insulin leads to Activation, insulin receptor
1379 Peptide Oxidation leads to Activation, JNK
2148 TLR4 activation leads to Activation, JNK
833 Covalent Binding, Protein leads to Activation, Keratinocytes
1395 Activation, mTORC1 leads to Activation, L-FABP
1400 Activation, AKT leads to Activation, L-FABP
1419 Activation, PI3K leads to Activation, L-FABP
476 Suppression, Constitutive androstane receptor, NR1l3 leads to Activation, LXR
535 Activation, PPARα leads to Activation, LXR alpha
2861 Increased, glutamate leads to Microglia activation
1393 Activation, mTORC2 leads to Activation, mTORC1
1398 Activation, AKT leads to Activation, mTORC1
1391 Activation, insulin receptor leads to Activation, mTORC2
1857 ACh Synaptic Accumulation leads to Activation, Muscarinic Acetylcholine Receptors
1236 Activation, PPARα leads to Activation, NADPH Oxidase
532 Activation, NRF2 leads to Activation, NR1H4
534 Activation, NR1H4 leads to Activation, PPARα
1408 Activation, FXR leads to Activation, PPARα
1409 Activation, SHP leads to Activation, PPARα
176 Activation, LXR leads to Activation, SCD-1
1403 Activation, SREBP-1 leads to Activation, SCD-1
533 Activation, NR1H4 leads to Activation, SHP
1407 Activation, FXR leads to Activation, SHP
946 Activation, Epidermal Growth Factor Receptor leads to Activation, Sp1
964 Activation, EGFR leads to Activation, Sp1
479 Activation, LXR leads to Activation, SREBF1
487 demethylation, PPARg promoter leads to Activation, SREBF1
1661 Activation, AKT2 leads to Activation, SREBF1
1394 Activation, AKT leads to Activation, SREBP-1
1399 Activation, mTORC1 leads to Activation, SREBP-1
1402 demethylation, PPARg promoter leads to Activation, SREBP-1
1421 Activation, aPKC leads to Activation, SREBP-1
177 Activation, LXR leads to Activation, SREBP-1c
68 Cell injury/death leads to Activation, Stellate cells
304 Up Regulation, TGFbeta1 expression leads to Activation, Stellate cells
1764 Increased pro-inflammatory mediators leads to Activation, Stellate cells
1778 Leukocyte recruitment/activation leads to Activation, Stellate cells
1015 Inhibition, Calcineurin Activity leads to Activation, Suppression of NFAT activation and hindrance of nuclear localization
1369 Activation, JAK/STAT pathway leads to Activation, TGF-beta pathway
2152 TGFbeta expression leads to Activation, TGF-beta pathway
2155 TLR4 activation leads to Activation, TGF-beta pathway
2156 Inactivation of PPARγ leads to Activation, TGF-beta pathway
1831 Cell injury/death leads to Activation, Tissue resident cells (Kuppfer cells)
1651 TGFbeta1 activation leads to TGFbeta pathway activation
379 Activation, Dendritic Cells leads to Activation/Proliferation, T-cells
380 Response, Keratinocytes leads to Activation/Proliferation, T-cells
2149 Activation, JNK leads to AP-1 activation
2251 TLR4 activation leads to AP-1 activation
1973 Blood extravasation into the lungs leads to Acute inhalation toxicity
1976 Impaired oxygenation of the blood leads to Acute inhalation toxicity
1588 Sensing of the stressor leads to Increased expression of APP
2053 Increased proinflammatory mediators leads to Increased expression of APP
2522 Binding to ACE2 leads to ADAM17 induction
2695 Reduced complex sphingolipids leads to Affected folate transporter
1837 Proteasomal dysfunction leads to Airway epithelial injury
2677 Epithelial-mesenchymal transition leads to Airway remodeling
2678 Fibroblast proliferation and differentiation leads to Airway remodeling
2440 CFTR Function, Decreased leads to ASL Height, Decreased
1265 Decline, Population leads to Alteration, Food-web structures
1097 Increased, PPAR-alpha activation leads to Alteration, lipid metabolism
35 N/A, Androgen receptor, Antagonism leads to Alteration, Wnt pathway
317 Altered, Transcription of genes by AR leads to Alteration, Wnt pathway
875 Activation, Long term AHR receptor driven direct and indirect gene expression changes leads to Alterations, Cellular proliferation / hyperplasia
996 N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects leads to Alterations, Cellular proliferation / hyperplasia
2842 Increase, Cell death leads to Altered Bone Cell Homeostasis
2843 Altered Signaling leads to Altered Bone Cell Homeostasis
2846 Oxidative Stress leads to Altered Bone Cell Homeostasis
2847 Energy Deposition leads to Altered Bone Cell Homeostasis
1807 Altered, Gene Expression leads to Altered differentiation
2601 Activation of TP53 leads to Altered differentiation
1268 Activation, Constitutive androstane receptor leads to Altered expression of hepatic CAR-dependent genes
18 Activation, AhR leads to Altered expression of AHR/ARNT pathway-dependent genes
2638 Increase, Mt Dysfunction leads to Altered expression of NRF2 pathway-dependent genes
242 N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin leads to Altered regulation, Alpha hemoglobin
1767 Inhibition, Aromatase leads to Altered regulation, Alpha hemoglobin
2771 Oxidative Stress leads to Altered Signaling
2856 Increase, DNA strand breaks leads to Altered Signaling
701 impaired, ion channels leads to Altered, Action Potential
2615 Altered kinetics of sodium channel leads to Altered, Action Potential
1142 Decreased, Thyroxine (T4) in tissues leads to Altered, Amphibian metamorphosis
1164 Decreased, Triiodothyronine (T3) in tissues leads to Altered, Amphibian metamorphosis
1201 Increased, Triiodothyronine (T3) in tissues leads to Altered, Amphibian metamorphosis
2168 T4 in serum, Decreased leads to Altered, Amphibian metamorphosis
2241 Increased, Thyroxine (T4) in serum leads to Altered, Amphibian metamorphosis
2244 Altered, TH-dependent gene expression leads to Altered, Amphibian metamorphosis
1309 Desensitization, Nicotinic acetylcholine receptor leads to Altered, Ca2+-calmodulin activated signal transduction
1311 N/A, Mitochondrial dysfunction 1 leads to Altered, Ca2+-calmodulin activated signal transduction
16 Altered expression of AHR/ARNT pathway-dependent genes leads to Altered, Cardiovascular development/function
976 Impairment, Endothelial network leads to Altered, Cardiovascular development/function
1351 Increase, COX-2 expression leads to Altered, Cardiovascular development/function
2691 Decrease, sox9 expression leads to Altered, Cardiovascular development/function
2727 Increase, slincR expression leads to Altered, Cardiovascular development/function
2765 Activation, AhR leads to Altered, Cardiovascular development/function
724 Binding, Tubulin leads to Altered, Chromosome number
738 Altered, Meiotic chromosome dynamics leads to Altered, Chromosome number
1296 Increased, ER binding to DNA (classical pathway) leads to Altered, Gene Expression
1297 Increased, ER binding to T.F. to DNA (non-classical pathway) leads to Altered, Gene Expression
1301 Increase, DNA Damage leads to Altered, Gene Expression
1302 Increased, Non-genomic signaling leads to Altered, Gene Expression
1806 Histone acetylation, increase leads to Altered, Gene Expression
2467 Increase, Cell death leads to Altered, inner ear development
280 Increase, Renal pathology due to VTG deposition leads to Altered, Larval development
737 Disorganization, Meiotic Spindle leads to Altered, Meiotic chromosome dynamics
2381 Increase, DNA Damage leads to Altered, Meiotic chromosome dynamics
2392 Ionizing Energy leads to Altered, Meiotic chromosome dynamics
2791 Cell cycle, disrupted leads to Altered, Meiotic chromosome dynamics
203 Altered, Neuroanatomy leads to Altered, Neurophysiology
2773 Altered Signaling leads to Altered, Nitric Oxide Levels
2774 Oxidative Stress leads to Altered, Nitric Oxide Levels
2779 Energy Deposition leads to Altered, Nitric Oxide Levels
1917 plasma retionic acid leads to Altered, Photoreceptor patterning
2378 Decreased, Triiodothyronine (T3) leads to Altered, Photoreceptor patterning
1298 Altered, Gene Expression leads to Altered, Protein Production
126 Agonism, Estrogen receptor leads to Altered, Reproductive behaviour
2373 Decreased, Triiodothyronine (T3) leads to Altered, retinal layer structure
2239 Decreased, Triiodothyronine (T3) in tissues leads to Altered, TH-dependent gene expression
2242 Increased, Thyroxine (T4) in serum leads to Altered, TH-dependent gene expression
2243 Increased, Triiodothyronine (T3) in tissues leads to Altered, TH-dependent gene expression
33 N/A, Androgen receptor, Antagonism leads to Altered, Transcription of genes by AR
2124 Decrease, AR activation leads to Altered, Transcription of genes by AR
2201 Antagonism, Androgen receptor leads to Altered, Transcription of genes by AR
1918 Altered, Photoreceptor patterning leads to Altered, Visual function
2374 Altered, retinal layer structure leads to Altered, Visual function
2377 Decreased, Eye size leads to Altered, Visual function
1969 Inhibition of LS function. leads to Alveolar collapse
1970 Alveolar collapse leads to Alveolar reopening
1566 hyperpolarisation, neuron leads to Analgesia
1570 Inhibition of neurotransmitter release leads to Analgesia
2517 Downregulation of ACE2 leads to Ang (1-7) levels reduced
2524 ACE2 increased shedding leads to Ang (1-7) levels reduced
2518 Ang (1-7) levels reduced leads to Degradation of Ang-II reduced
2123 Antagonism, Androgen receptor leads to AGD, decreased
2127 Altered, Transcription of genes by AR leads to AGD, decreased
2129 decrease, transcription of genes by AR leads to AGD, decreased
2820 Decrease, AR activation leads to AGD, decreased
2612 Increase activation, Nuclear factor kappa B (NF-kB) leads to Antagonism, Estrogen receptor
1572 hyperpolarisation, neuron leads to Anti-depressant Activity
1573 Inhibition of neurotransmitter release leads to Anti-depressant Activity
1341 Mitochondrial impairment leads to Apoptosis
1365 Activation, HIF-1 leads to Apoptosis
1366 Increased, DNA Damage-Repair leads to Apoptosis
1367 Damaging, Mitochondria leads to Apoptosis
1712 Cell cycle, disrupted leads to Apoptosis
1716 Histone deacetylase inhibition leads to Apoptosis
1866 Unfolded Prortein Response leads to Apoptosis
2190 Increase,Oxidative DNA damage leads to Apoptosis
2569 Activation, AhR leads to Apoptosis
2671 Non-coding RNA expression,alteration leads to Apoptosis
2882 Decrease, GLI1/2 target gene expression leads to Apoptosis
2193 Mitochondrial dysfunction leads to Apoptotic cell death
2200 ER stress leads to Apoptotic cell death
1594 Foam cell formation leads to Atherosclerosis
2860 Systemic APR leads to Atherosclerosis
2070 Porcupine-induced Wnt secretion and Wnt signaling activation leads to beta-catenin activation
927 Inhibition, Bile Salt Export Pump (ABCB11) leads to Bile accumulation, Pathological condition
2593 Increased AngII leads to Binding of agonist, Angiotensin II receptor type 1 receptor (AT1R)
332 Production, VEGF-A leads to Binding, VEGF-A
2024 Inhibition of JAK3 leads to STAT5 inhibition
1972 Loss of barrier function leads to Blood extravasation into the lungs
2174 Loss of alveolar capillary membrane integrity leads to Blood extravasation into the lungs
1169 Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage) leads to Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tis
2352 Hypofibrinolysis leads to Bradykinin, activated
1841 Fibroproliferative airway lesions leads to Bronchiolitis obliterans
1194 Anticoagulant rodenticide interferes with gamma-carboxyglutamate formation, Inhibition of p leads to Calcium cannot bind to the hydroxyapatite matrix of bone, Osteocalcin and other bone protei
1711 p21 (CDKN1A) expression, increase leads to Cell cycle, disrupted
1715 Histone deacetylase inhibition leads to Cell cycle, disrupted
1997 Histone acetylation, increase leads to Cell cycle, disrupted
2790 Increase, DNA Damage leads to Cell cycle, disrupted
269 Alkylation, Protein leads to Cell injury/death
353 BDNF, Reduced leads to Cell injury/death
363 N/A, Mitochondrial dysfunction 1 leads to Cell injury/death
1686 Glutamate dyshomeostasis leads to Cell injury/death
1687 Neuroinflammation leads to Cell injury/death
1690 Oxidative Stress leads to Cell injury/death
1719 Increased pro-inflammatory mediators leads to Cell injury/death
1829 Activation, Caspase 8 pathway leads to Cell injury/death
1862 Increased, Intracellular Calcium overload leads to Cell injury/death
1943 Impaired, Proteostasis leads to Cell injury/death
2766 Increase, Cytosolic Ca leads to Cell injury/death
2768 Decrease, ATP pool leads to Cell injury/death
2788 Increase, Cell membrane depolarization leads to Cell injury/death
2797 Increase, Mitochondrial swelling leads to Cell injury/death
2870 decreased, Bcl-2 expression leads to Cell injury/death
2871 increased, Bax expression leads to Cell injury/death
2889 N/A, Liver Steatosis leads to Cell injury/death
874 Activation, Long term AHR receptor driven direct and indirect gene expression changes leads to Changes/Inhibition, Cellular Homeostasis and Apoptosis
1812 Decreased proximal tubular vectorial transport leads to Chemical induced Fanconi syndrome
319 Activation of specific nuclear receptors, Transcriptional change leads to Cholestasis, Pathology
929 Increase, Inflammation leads to Cholestasis, Pathology
931 Production, Reactive oxygen species leads to Cholestasis, Pathology
932 Peptide Oxidation leads to Cholestasis, Pathology
2329 Increased Sodium-sensitive hypertension leads to Chronic kidney disease
2679 Pulmonary inflammation leads to Chronic obstructive pulmonary disease
2680 Emphysema leads to Chronic obstructive pulmonary disease
2681 Airway remodeling leads to Chronic obstructive pulmonary disease
1315 Increase, Mucin production leads to Chronic, Mucus hypersecretion
2471 Goblet cell metaplasia leads to Chronic, Mucus hypersecretion
2472 Goblet cell hyperplasia leads to Chronic, Mucus hypersecretion
2441 ASL Height, Decreased leads to CBF, Decreased
2445 Mucus Viscosity, Increased leads to CBF, Decreased
2448 Motile Cilia Number/Length, Decreased leads to CBF, Decreased
2451 Oxidative Stress leads to CBF, Decreased
549 Increased, Induced Mutations in Critical Genes leads to Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF)
551 Formation, Pro-mutagenic DNA Adducts leads to Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF)
2289 Oxidative Stress leads to Coagulation
2359 Diminished Protective Response to ROS leads to Coagulation
383 Thyroperoxidase, Inhibition leads to Cognitive Function, Decreased
384 Altered, Neurophysiology leads to Cognitive Function, Decreased
403 T4 in serum, Decreased leads to Cognitive Function, Decreased
748 Hippocampal Physiology, Altered leads to Cognitive Function, Decreased
1948 TR Antagnoism leads to Cognitive Function, Decreased
2411 Neuronal network function, Decreased leads to Cognitive Function, Decreased
2412 Increased Cholinergic Signaling leads to Cognitive Function, Decreased
2800 methemocyanin formation (decrease overall oxygen binding capacity) leads to Hemocyanin Bohr effect decrease
1357 Expression of Collagen leads to Collagen Deposition
1779 EMT leads to Collagen Deposition
1803 Reduced neural crest cell migration leads to Reduced collagen production
1805 Histone deacetylase inhibition leads to Reduced collagen production
2275 11β-hydroxylase inhibition leads to Cortisol and 11β-(OH) testosterone decreased
1273 Sensory Airway Irritation leads to Cough, Dyspnea, Sneezing, Acute respiratory effect
1275 Excitation, Trigeminal nerve excitation leads to Cough, Dyspnea, Sneezing, Acute respiratory effect
2449 Oxidative Stress leads to CFTR Function, Decreased
836 Inhibition, Phospholipase A leads to Damage, Lipid bilayer
321 Accumulation, Triglyceride leads to Damaging, Mitochondria
1363 Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK leads to Damaging, Mitochondria
241 Propagation, Oxidative stress leads to Damaging, Red blood cells; hemolysis
245 N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin leads to Damaging, Red blood cells; hemolysis
559 Decrease, Number of worker bees leads to Death/Failure, Colony
563 impaired, Larval development leads to Death/Failure, Colony
574 impaired, Hive thermoregulation leads to Death/Failure, Colony
1145 Weakened, Colony leads to Death/Failure, Colony
135 Decrease, Fecundity leads to Decline, Population
199 Increase, Mortality leads to Decline, Population
200 Increased Mortality leads to Decline, Population
1264 Increased, Male offspring leads to Decline, Population
1919 Altered, Visual function leads to Decline, Population
2142 Reduction, Cumulative fecundity and spawning leads to Decline, Population
1991 Decrease of egg production and cummulative fecundity leads to Decline, Population trajectory
2486 Increased Mortality leads to Decline, Population trajectory
1780 Mitochondrial Complex I inhibition leads to Decrease in mitochondrial oxidative phosphorylation
1781 Increase, Mitochondrial complex III antagonism leads to Decrease in mitochondrial oxidative phosphorylation
1782 Mitochondrial Complex IV inhibition leads to Decrease in mitochondrial oxidative phosphorylation
1783 Mitochondrial Complex V inhibition leads to Decrease in mitochondrial oxidative phosphorylation
1940 Inhibition, NADH-ubiquinone oxidoreductase (complex I) leads to Decrease in mitochondrial oxidative phosphorylation
1990 Impaired ovulation leads to Decrease of egg production and cummulative fecundity
2387 impaired, Fertility leads to Decrease of egg production and cummulative fecundity
2388 Decreased spermatogenesis leads to Decrease of egg production and cummulative fecundity
2395 Ionizing Energy leads to Decrease of egg production and cummulative fecundity
2400 Increase, Oocyte apoptosis leads to Decrease of egg production and cummulative fecundity
870 BDNF, Reduced leads to GABAergic interneurons, Decreased
1505 TH synthesis, Decreased leads to GABAergic interneurons, Decreased
358 Synaptogenesis, Decreased leads to Neuronal network function, Decreased
368 N/A, Neurodegeneration leads to Neuronal network function, Decreased
582 N/A, Mitochondrial dysfunction 1 leads to Neuronal network function, Decreased
659 Desensitization, Nicotinic acetylcholine receptor leads to Neuronal network function, Decreased
1688 Cell injury/death leads to Neuronal network function, Decreased
1691 Glutamate dyshomeostasis leads to Neuronal network function, Decreased
2410 Increased Cholinergic Signaling leads to Neuronal network function, Decreased
2500 Neuroinflammation leads to Neuronal network function, Decreased
2504 Dysfunctional synapses leads to Neuronal network function, Decreased
355 Cell injury/death leads to Synaptogenesis, Decreased
356 Aberrant, Dendritic morphology leads to Synaptogenesis, Decreased
357 Reduced, Presynaptic release of glutamate leads to Synaptogenesis, Decreased
447 Delay, Developmental GABA shift leads to Synaptogenesis, Decreased
448 BDNF, Reduced leads to Synaptogenesis, Decreased
759 Neuroinflammation leads to Synaptogenesis, Decreased
871 GABAergic interneurons, Decreased leads to Synaptogenesis, Decreased
442 Inhibition, Na+/I- symporter (NIS) leads to Thyroidal Iodide, Decreased
1197 Inhibition, Iodotyrosine deiodinase (IYD) leads to Thyroidal Iodide, Decreased
2751 Increase, Incomplete ecdysis leads to Decrease, hatching of egg
1008 Decrease, Circulating ETH leads to Decrease, Abdominal muscle contraction
1349 Decrease, Excitatory postsynaptic potential leads to Decrease, Abdominal muscle contraction
2266 Activation, Glucocorticoid Receptor leads to Decrease, ACAD
2095 Decrease, OXPHOS leads to Decrease, ATP pool
2098 Decrease, Neutral lipids leads to Decrease, ATP pool
2176 Decrease, ATP synthase activity leads to Decrease, ATP pool
2203 Decrease, Coupling of OXPHOS leads to Decrease, ATP pool
2208 Decrease, FAO leads to Decrease, ATP pool
2228 N/A, Mitochondrial dysfunction 1 leads to Decrease, ATP pool
2229 Increase, Mitochondrial ATP synthase antagonism leads to Decrease, ATP pool
2230 Increase, Mitochondrial complex III antagonism leads to Decrease, ATP pool
1935 Decrease, DHT level leads to Decrease, AR activation
1936 Decrease, testosterone level leads to Decrease, AR activation
2130 Antagonism, Androgen receptor leads to Decrease, AR activation
2131 reduction, testosterone levels leads to Decrease, AR activation
936 Activation, Epidermal Growth Factor Receptor leads to Decreased ciliated cell apoptosis
962 Activation, EGFR leads to Decreased ciliated cell apoptosis
256 demethylation, PPARg promoter leads to Decrease, Aromatase (Cyp19a1)
1663 Increase, Uncoupling of photophosphorylation leads to Decrease, ATP production
2334 Decrease, Photosynthesis leads to Decrease, ATP production
2175 Decrease, Coupling of OXPHOS leads to Decrease, ATP synthase activity
2343 Decrease, Photosynthesis leads to Decrease, ATP synthase activity
2346 Decrease, OXPHOS leads to Decrease, ATP synthase activity
792 Inhibition, 5α-reductase activity leads to Decrease, Bioactivation of testosterone
1756 Decrease, Calcium currents leads to Decrease, Calcium binding to Troponin C
1755 Blockade, L-Type Calcium Channels leads to Decrease, Calcium currents
1757 Decrease, Calcium binding to Troponin C leads to Decrease, Cardiac contractility
1762 Disruption, Sarcomere assembly leads to Decrease, Cardiac contractility
2823 Decrease, Mitochondrial ATP production leads to Decrease, Cardiac contractility
1758 Decrease, Cardiac contractility leads to Decrease, Cardiac ejection fraction
2204 Decrease, ATP pool leads to Decrease, Cell proliferation
2404 Overexpression of rasl11b leads to Decrease, Cell proliferation
2722 Decrease, GLI1/2 target gene expression leads to Decrease, Cell proliferation
2732 Decrease, SHH second messenger production leads to Decrease, Cell proliferation
2795 Decrease, Glucose pool leads to Decrease, Cell proliferation
2753 Decrease, knickkopf gene leads to Decrease, Chitin laminar organization
1664 Decrease, ATP production leads to Decrease, Chlorophyll synthesis
1346 Decrease, Circulating ETH leads to Decrease, Circulating CCAP
998 Increase, EcR agonism leads to Decrease, Circulating ETH
1345 Increase, Ftz-f1 expression leads to Decrease, Circulating ETH
1599 Increase, LPO leads to Decrease, Coupling of OXPHOS
1754 Increase, ROS production leads to Decrease, Coupling of OXPHOS
1742 Inhibition, CHS-1 leads to Decrease, Cuticular chitin content
1747 Increase, Opening of voltage-dependent calcium channel leads to Decrease, Cuticular chitin content
1417 Increase, Fatty acid β-oxidation leads to Decrease, cytosolic fatty acid
1009 Decreased, Synthesis of molting fluid proteases leads to Decrease, Digestion of old cuticle
2170 Inhibition, Chitinase leads to Decrease, Digestion of old cuticle
2172 Inhibition, Chitobiase leads to Decrease, Digestion of old cuticle
1880 5α-reductase, inhibition leads to Decrease, DHT level
1934 Decrease, testosterone level leads to Decrease, DHT level
2126 reduction, testosterone levels leads to Decrease, DHT level
2744 Decrease, Tyrosine leads to Decrease, dopa decarboxylase
1085 Decreased, Ovarian E2 leads to Decrease, E2 blood concentrations at hypothalamus
1086 Suppression, Estrogen receptor (ER) activity leads to Decrease, E2 blood concentrations at hypothalamus
1347 Decrease, Circulating CCAP leads to Decrease, Ecdysis motoneuron bursts
1348 Decrease, Ecdysis motoneuron bursts leads to Decrease, Excitatory postsynaptic potential
1994 Increase, hypermethylation of the promotor region of GnRHR leads to Decease, expression of GnRHR
2207 Decrease, Lipid storage leads to Decrease, FAO
198 Increase, Mortality leads to Decrease, Fecundity
261 Induction, Pre-mature molting leads to Decrease, Fecundity
1752 Decrease, Oogenesis leads to Decrease, Fecundity
1753 Decrease, Ovulation leads to Decrease, Fecundity
1885 Increase, Gene expression leads to Decrease, Fecundity
2211 Increase, Follicular atresia leads to Decrease, Fecundity
2560 Increase, Ovarian follicle breakdown leads to Decrease, Fecundity
2620 Decreased spermatogenesis leads to Decrease, Fecundity
2114 Decrease, Oogenesis (F3) leads to Decrease, Fecundity (F3)
393 irregularities, ovarian cycle leads to Decrease, Fertility
808 malformed, Male reproductive tract leads to Decrease, Fertility
1471 Decrease, Ovulation leads to Decrease, Fertility
2164 Impaired, Spermatogenesis leads to Decrease, Fertility
2165 Decreased, 11KT leads to Decrease, Fertility
2721 Decrease, GLI1/2 translocation leads to Decrease, GLI1/2 target gene expression
2720 Antagonism Smoothened leads to Decrease, GLI1/2 translocation
2735 Decrease, SMO relocation leads to Decrease, GLI1/2 translocation
2101 Increase, DNMT inhibition leads to Decrease, Global DNA methylation
2794 Increase, Glycolysis leads to Decrease, Glucose pool
2529 Decrease, GLUT4 leads to Decrease, Glucose uptake
2528 Increase, TNF leads to Decrease, GLUT4
1667 Decrease, Photosynthesis leads to Decrease, Glycolysis
1739 Decrease, Mitochondrial ATP production leads to Decrease, Growth
1741 Increase, Apoptosis leads to Decrease, Growth
2178 Increase, Tissue/organ damage leads to Decrease, Growth
2205 Decrease, Cell proliferation leads to Decrease, Growth
2215 Increase, Cell death leads to Decrease, Growth
2218 Decrease, Lipid storage leads to Decrease, Growth
2283 Decrease, Leaf development leads to Decrease, Growth
2767 Cell injury/death leads to Decrease, Growth
2802 behavioral change leading to possible reduced feeding opportunity leads to Decrease, Growth
2110 Decrease, Global DNA methylation leads to Decrease, Heritable DNA methylation (F3)
1061 Antagonism, Histamine Receptor (H2) leads to Decrease, histaminergic neuron excitation
790 Thyroperoxidase, Inhibition leads to Decrease, Incorporation of active iodide into iodotyrosines
2752 Decrease, 20-hydroxyecdysone leads to Decrease, knickkopf gene
1670 Decrease, Mitochondrial ATP production leads to Decrease, Leaf cell mitosis
1671 Decrease, Leaf cell mitosis leads to Decrease, Leaf development
2339 Increase, Programmed cell death leads to Decrease, Leaf development
2341 Decrease, ATP production leads to Decrease, Leaf development
2344 Decrease, ATP synthase activity leads to Decrease, Leaf development
1478 Activation, PTGS-2 leads to Decrease, leukocyte adherence
1665 Decrease, Chlorophyll synthesis leads to Decrease, Light harvest capacity
2206 Increase, LPO leads to Decrease, Lipid storage
2217 Increase, Fatty acid β-oxidation leads to Decrease, Lipid storage
1314 Chronic, Mucus hypersecretion leads to Decreased lung function
2367 Reduced tidal volume leads to Decreased lung function
2370 Inhibition of LS function. leads to Decreased lung function
2371 Alveolar collapse leads to Decreased lung function
2372 Loss of alveolar capillary membrane integrity leads to Decreased lung function
2443 MCC, Decreased leads to Decreased lung function
2859 Increase, Mucin production leads to Decreased lung function
188 Disruption, Mitochondrial electron transport chain leads to Decrease, Mitochondrial ATP production
1600 Decrease, Coupling of OXPHOS leads to Decrease, Mitochondrial ATP production
1669 Decrease, OXPHOS leads to Decrease, Mitochondrial ATP production
1681 Dysfunction, Mitochondria leads to Decrease, Mitochondrial ATP production
1738 Decrease, Glycolysis leads to Decrease, Mitochondrial ATP production
2822 N/A, Mitochondrial dysfunction 1 leads to Decrease, Mitochondrial ATP production
2093 Increase, ROS production leads to Decrease, MMP
2337 Increase in RONS leads to Decrease, MMP
2345 Increase, ROS leads to Decrease, MMP
2550 Increased, Reactive oxygen species leads to Decrease, MMP
2636 Inhibition, ETC complexes of the respiratory chain leads to Decrease, MMP
2097 Increase, LPO leads to Decrease, Neutral lipids
2757 Weak, Procuticle protection leads to Decrease, New cuticle secretion
558 Reduced, Food storage leads to Decrease, Number of worker bees
569 Abnormal, Foraging activity and behavior leads to Decrease, Number of worker bees
572 impaired, Development leads to Decrease, Number of worker bees
580 Abnormal, Roll change within caste leads to Decrease, Number of worker bees
663 Accelerated, Aging leads to Decrease, Number of worker bees
1469 Increase, Apoptosis leads to Decrease, Oogenesis
1597 Increase, Follicular atresia leads to Decrease, Oogenesis
1601 Decrease, Mitochondrial ATP production leads to Decrease, Oogenesis
2104 Increase, Oocyte apoptosis leads to Decrease, Oogenesis
2107 Increase, Ovarian follicle breakdown leads to Decrease, Oogenesis
2209 Decrease, ATP pool leads to Decrease, Oogenesis
2113 Increase, Oocyte apoptosis (F3) leads to Decrease, Oogenesis (F3)
2118 Increase, Ovarian follicle breakdown (F3) leads to Decrease, Oogenesis (F3)
685 Reduced, Prostaglandins, ovary leads to Decrease, Ovulation
1470 Decrease, Oogenesis leads to Decrease, Ovulation
1668 Decrease, Glycolysis leads to Decrease, OXPHOS
1809 Inhibition, NADH-ubiquinone oxidoreductase (complex I) leads to Decrease, OXPHOS
1872 Increase, Mitochondrial complex III antagonism leads to Decrease, OXPHOS
2094 Decrease, MMP leads to Decrease, OXPHOS
2119 Increase, Mitochondrial ATP synthase antagonism leads to Decrease, OXPHOS
2709 Increased, Intracellular Calcium overload leads to Decrease, OXPHOS
2724 Decrease, Cell proliferation leads to Decrease, outgrowth
2725 Increase, Apoptosis leads to Decrease, outgrowth
2792 Apoptosis leads to Decrease, outgrowth
2805 Decrease, GLI1/2 target gene expression leads to Decrease, outgrowth
1666 Decrease, Light harvest capacity leads to Decrease, Photosynthesis
1737 Decrease, PSII activity leads to Decrease, Photosynthesis
2333 Decrease, Photosystem II efficiency leads to Decrease, Photosynthesis
1736 Increase, D1 protein antagonism leads to Decrease, PSII activity
2332 D1 protein deactivation leads to Decrease, Photosystem II efficiency
2340 Increase, OEC damage leads to Decrease, Photosystem II efficiency
2179 Decrease, ATP pool leads to Decrease, ATPase activity
51 Increased Cholinergic Signaling leads to Decrease, Population growth rate
94 Reduction, Cumulative fecundity and spawning leads to Decrease, Population growth rate
675 Reduced, Reproductive Success leads to Decrease, Population growth rate
1472 Decrease, Fertility leads to Decrease, Population growth rate
1886 Decrease, Fecundity leads to Decrease, Population growth rate
1895 Reduction fo Pigmentation pattern leads to Decrease, Population growth rate
2013 Increased Mortality leads to Decrease, Population growth rate
2015 Impaired coordination and movement leads to Decrease, Population growth rate
2016 AchE Inhibition leads to Decrease, Population growth rate
2081 Reduced, Swimming performance leads to Decrease, Population growth rate
2115 Decrease, Fecundity (F3) leads to Decrease, Population growth rate
2143 Altered, Visual function leads to Decrease, Population growth rate
2147 Increased, Male Biased Sex Ratio leads to Decrease, Population growth rate
2169 Decrease, Growth leads to Decrease, Population growth rate
2292 impaired, Fertility leads to Decrease, Population growth rate
2336 Decrease, Reproduction leads to Decrease, Population growth rate
2463 Increase, Mortality leads to Decrease, Population growth rate
2624 Decreased spermatogenesis leads to Decrease, Population growth rate
2634 Increase, predation leads to Decrease, Population growth rate
2635 Decreased, Reproductive Success leads to Decrease, Population growth rate
2693 Viable offspring, decreased leads to Decrease, Population growth rate
2754 Decrease, knickkopf gene leads to Decrease, Prevent chitin degradation by chitinases
2335 Decrease, Leaf development leads to Decrease, Reproduction
2547 Decrease, ATP production leads to Decrease, Reproduction
2551 Decrease, Mitochondrial ATP production leads to Decrease, Reproduction
2553 Increase, Programmed cell death leads to Decrease, Reproduction
2555 Increase, Pollen abnormal leads to Decrease, Reproduction
2586 Decrease, Oogenesis leads to Decrease, Reproduction
2621 Decrease, Fecundity leads to Decrease, Reproduction
2623 Decreased spermatogenesis leads to Decrease, Reproduction
768 Decreased, Uptake of inorganic iodide leads to Decrease, Serum thyroid hormone (T4/T3)
791 Decrease, Incorporation of active iodide into iodotyrosines leads to Decrease, Serum thyroid hormone (T4/T3)
2734 Antagonism Smoothened leads to Decrease, SMO relocation
2731 Decrease, GLI1/2 target gene expression leads to Decrease, SHH second messenger production
2682 dimerization, AHR/ARNT leads to Decrease, sox9 expression
2684 Increase, slincR expression leads to Decrease, sox9 expression
2688 Activation, AhR leads to Decrease, sox9 expression
369 Activation, PPARα leads to Decrease, Steroidogenic acute regulatory protein (STAR)
1487 Increase, ammonium (NH4+) leads to Decrease, surfactant
1488 Activate, phospholipase leads to Decrease, surfactant
1932 Reduction, DHEA leads to Decrease, testosterone level
1933 Reduction, androstenedione leads to Decrease, testosterone level
2128 Decrease, AR activation leads to decrease, transcription of genes by AR
1887 Increase, DNA hypomethylation leads to Decrease, Transgenerational DNA methylation
370 Activation, PPARα leads to Decrease, Translocator protein (TSPO)
1615 decreased reward leads to decreased DNA methylation of tyrosine hydroxylase
1613 chronic high fat diet leads to decreased dopamine
1617 decreased reward leads to decreased dopamine
1620 decreased DNA methylation of tyrosine hydroxylase leads to decreased dopamine
1621 decreased methylation of dopamine transporter promoter leads to decreased dopamine
2480 Ovarian follicle pool, reduced leads to Decreased fertility, Reduced number of oocytes ovulated
2696 Affected folate transporter leads to decrease folate
1616 decreased reward leads to decreased methylation of dopamine transporter promoter
2064 Increase, the risk of acute respiratory failure leads to Decreased mortality
1810 Decrease, OXPHOS leads to Decreased Na/K ATPase activity
2786 Decrease, ATP pool leads to Decreased Na/K ATPase activity
2278 Decreased plasma Cortisol level leads to decreased oocyte maturation
2276 Cortisol and 11β-(OH) testosterone decreased leads to Decreased plasma Cortisol level
1916 retinoic acid leads to plasma retionic acid
1765 Binding, SH/SeH proteins involved in protection against oxidative stress leads to Protection against oxidative stress, decreased
1811 Decreased Na/K ATPase activity leads to Decreased proximal tubular vectorial transport
1915 Retinaldehyde dehydrogenase leads to retinoic acid
1614 decreased dopamine leads to decreased reward
2610 Increase,miRNA levels leads to Decrease,SIRT1(sirtuin 1) levels
1649 Reduction, testosterone level leads to Decreased sperm quantity or quality in the adult, Decreased fertility
2166 Decreased, 11KT leads to Decreased spermatogenesis
2384 Altered, Meiotic chromosome dynamics leads to Decreased spermatogenesis
2393 Ionizing Energy leads to Decreased spermatogenesis
2619 Increase, Apoptosis leads to Decreased spermatogenesis
2622 Increase, DNA Damage leads to Decreased spermatogenesis
2072 Decreased, cholesterol leads to Decreased, 11KT
2134 Activation, PPARα leads to Decreased, 11KT
2158 11β-hydroxylase inhibition leads to Decreased, 11KT
2162 Inhibition of 11β-HSD leads to Decreased, 11KT
2277 Cortisol and 11β-(OH) testosterone decreased leads to Decreased, 11KT
154 Decreased, HSD17B10 expression leads to Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity
1529 Increased, extracellular serotonin leads to Decreased, 5-HT3
2401 ALDH1A (RALDH), inhibition leads to Decreased, atRA concentration
2629 Decreased, Gonadotropins leads to Decreased , Androgen and Progestin
1541 Reduced, PTGS2 function leads to Decreased, angiogenesis
644 Increased, serotonin (5-HT) leads to Decreased, anxiety
1304 Altered, Protein Production leads to Decreased, Apoptosis (Epithelial Cells)
800 Increased, HIF-1 heterodimer leads to Decreased, Aromatase (Cyp19a1) mRNA
2868 Increased, glutamate leads to decreased, Bcl-2 expression
1539 Reduced, PTGS1 function leads to Decreased, bicarbonate
1095 Increased, PPAR-alpha activation leads to Decreased, bile flow
885 Increased, Catabolism of Muscle Protein leads to Decreased, Body Weight
213 Inhibition, NMDARs leads to Decreased, Calcium influx
1245 Decreased, GABA release leads to Decreased, Chloride conductance
805 Decreased, mevalonate leads to Decreased, cholesterol
2073 Activation, PPARα leads to Decreased, cholesterol
1429 Decreased, serotonin transporter activity leads to Decreased, extracellular chloride (Cl-)
1434 Decreased, synaptic release leads to Decreased, extracellular serotonin
1521 Increased, extracellular serotonin leads to Decreased, extracellular serotonin
1528 Increased, serotonin transporter activity leads to Decreased, extracellular serotonin
1428 Decreased, serotonin transporter activity leads to Decreased, extracellular Na+
2376 Decreased, Triiodothyronine (T3) leads to Decreased, Eye size
2405 Decrease, Cell proliferation leads to Decreased, Eye size
1551 Reduced, presynaptic neuron 2 activity leads to Decreased, GABA
1244 Decreased, sodium conductance 2 leads to Decreased, GABA release
1186 Increased, serotonin (5-HT) 1 leads to Decreased, gametogenesis
817 Occurrence, Cytoplasmic vacuolization (Renal tubule) leads to Decreased, Glomerular filtration
821 Occurrence, Cystic dilatation (renal tubule) leads to Decreased, Glomerular filtration
825 Occurrence, Cytoplasmic vacuolization (podocyte) leads to Decreased, Glomerular filtration
2627 Increased, Kisspeptin signalling leads to Decreased, Gonadotropins
2628 Agonism, Estrogen Receptor alpha leads to Decreased, Gonadotropins
2666 Activation, estrogen receptor alpha leads to Decreased, Gonadotropins
257 Decreased, PPAR-alpha activation leads to Decreased, HSD17B10 expression
259 Decreased, PPAR-beta activation leads to Decreased, HSD17B10 expression
260 Decreased, PPAR-gamma activation leads to Decreased, HSD17B10 expression
576 Decreased, Glucose oxidase enzyme activity leads to Decreased, Hydrogen peroxide production
2872 Impairment, Learning and memory leads to decreased, IQ
1553 Reduced, GABA-A receptor activation leads to Decreased, intracellular chloride
1431 Decreased, serotonin transporter activity leads to Decreased, intracellular serotonin
1243 Decreased, sodium conductance 2 leads to Decreased, Ionotropic GABA receptor chloride channel conductance
524 Down Regulation, HMGCS2 leads to Decreased, Ketogenesis
880 Decreased, PPARalpha transactivation of gene expression leads to Decreased, Ketogenesis (production of ketone bodies)
882 Decreased, Mitochondrial Fatty Acid Beta Oxidation leads to Decreased, Ketogenesis (production of ketone bodies)
1749 Fatty Acid Beta Oxidation, Decreased leads to Decreased, Ketogenesis (production of ketone bodies)
1108 Decreased, GnRH pulsatility/release in hypothalamus leads to Decreased, LH Surge from anterior pituitary
650 N/A, sedation leads to Decreased, locomotion
1644 Impairment, Learning and memory leads to Decreased, locomotion
212 Decreased, Nitric Oxide leads to Decreased, Long-term potentiation (LTP)
388 Suppression, Inflammatory cytokines leads to Decreased, Lymphocytes
2630 Decreased , Androgen and Progestin leads to Decreased, Maturation Inducing Steroids Surge by Granulosa cells
804 Inhibition, HMG-CoA reductase leads to Decreased, mevalonate
879 Decreased, PPARalpha transactivation of gene expression leads to Decreased, Mitochondrial Fatty Acid Beta Oxidation
881 Decreased, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids leads to Decreased, Mitochondrial Fatty Acid Beta Oxidation
2039 Activation, Glucocorticoid Receptor leads to Decreased, Mitochondrial Fatty Acid Beta Oxidation
2267 Decrease, ACAD leads to Decreased, Mitochondrial Fatty Acid Beta Oxidation
9 Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity leads to Decreased, Mitochondrial fatty acid beta-oxidation
520 Down Regulation, CPT1A leads to Decreased, Mitochondrial fatty acid beta-oxidation
2902 ERa inactivation leads to Decreased, Mitochondrial fatty acid beta-oxidation
1534 Reduced, PTGS1 function leads to Decreased, mucosal blood flow
1537 Reduced, PTGS1 function leads to Decreased, mucous
647 N/A, Neurodegeneration leads to Decreased, Neuronal network function in adult brain
892 Increased, Intracellular Calcium overload leads to Decreased, Neuronal network function in adult brain
1447 Reduce expression, BDNF leads to Decreased, neuroplasticity
1523 Reduced, BDNF leads to Decreased, neuroplasticity
282 Increase, ROS production leads to Decreased, Nitric Oxide
2799 methemocyanin formation (decrease overall oxygen binding capacity) leads to Decrease overall oxygen binding capacity (methemocyanin formation)
1432 Decreased, intracellular serotonin leads to Decreased, packaged serotonin
499 Activation, AhR leads to Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway)
878 Decreased, PPARalpha transactivation of gene expression leads to Decreased, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids
756 Increased Mortality leads to Decreased, population 1
1004 Increase, Mortality leads to Decreased, population 1
1013 Increase, Mortality leads to Decreased, Population size
1191 Increased Mortality leads to Decreased, Population size
2389 Decrease of egg production and cummulative fecundity leads to Decreased, Population size
2396 Ionizing Energy leads to Decreased, Population size
428 Increased Mortality leads to Decreased, Population trajectory
453 AchE Inhibition leads to Decreased, Population trajectory
2556 Decrease, Reproduction leads to Decreased, Population trajectory
2041 Activation, Glucocorticoid Receptor leads to Decreased, PPAR-alpha activation
877 Binding as antagonist, Antagonist binding to PPARalpha ligand binding domain leads to Decreased, PPARalpha transactivation of gene expression
1024 stabilization, PPAR alpha co-repressor leads to Decreased, PPARalpha transactivation of gene expression
734 Increased, Estrogen receptor (ER) activity leads to Decreased, Progesterone from corpus luteum
732 Increase, Dopaminergic activity leads to Decreased, Prolactin
1137 Inhibition, Cyclooxygenase 1 activity leads to Decreased, Prostaglandin F2alpha concentration, plasma
681 Inhibition, Cyclooxygenase activity leads to Decreased, Prostaglandin F2alpha synthesis, ovary
820 Occurrence, Cytoplasmic vacuolization (Renal tubule) leads to Decreased, Renal ability to dilute urine
824 Occurrence, Cystic dilatation (renal tubule) leads to Decreased, Renal ability to dilute urine
828 Occurrence, Cytoplasmic vacuolization (podocyte) leads to Decreased, Renal ability to dilute urine
818 Occurrence, Cytoplasmic vacuolization (Renal tubule) leads to Decreased, Renal plasma flow
822 Occurrence, Cystic dilatation (renal tubule) leads to Decreased, Renal plasma flow
826 Occurrence, Cytoplasmic vacuolization (podocyte) leads to Decreased, Renal plasma flow
1179 premature, spawning 1 leads to Decreased, Reproductive Success
1182 Delayed, Sexual maturity leads to Decreased, Reproductive Success
1188 Decreased, gametogenesis leads to Decreased, Reproductive Success
1193 increased or inappropriate, mantel display leads to Decreased, Reproductive Success
1221 induced, parturition leads to Decreased, Reproductive Success
1222 premature, Spawning leads to Decreased, Reproductive Success
1323 Induced parturition leads to Decreased, Reproductive Success
1324 induced spawning leads to Decreased, Reproductive Success
1499 Sexual behavior, decreased leads to Decreased, Reproductive Success
1500 Locomotor activity, decreased leads to Decreased, Reproductive Success
2804 Decrease, Growth leads to Decreased, Reproductive Success
1520 Inhibit, serotonin transporter activity leads to Decreased, serotonin transporter activity
1064 Increased, T4/T3 catabolism leads to Decreased, serum T4/T3
645 Decreased, anxiety leads to Decreased, sheltering
585 Inhibition, sodium channel leads to Decreased, Sodium conductance 1
597 Inhibition, Ether-a-go-go (ERG) voltage-gated potassium channel leads to Decreased, Sodium conductance 1
1242 Inhibition, sodium channel leads to Decreased, sodium conductance 2
819 Occurrence, Cytoplasmic vacuolization (Renal tubule) leads to Decreased, Sodium reabsorption
823 Occurrence, Cystic dilatation (renal tubule) leads to Decreased, Sodium reabsorption
827 Occurrence, Cytoplasmic vacuolization (podocyte) leads to Decreased, Sodium reabsorption
654 Increased, predation leads to Decreased, survival
1642 Reduced, Swimming performance leads to Decreased, survival
1433 Decreased, packaged serotonin leads to Decreased, synaptic release
1519 Decreased, extracellular serotonin leads to Decreased, synaptic release
999 Increase, EcR agonism leads to Decreased, synthesis and secretion of molting fluid proteases
1007 Increase, EcR agonism leads to Decreased, Synthesis of molting fluid proteases
806 Decreased, cholesterol leads to Decreased, Testosterone
729 Decreased, Androgen receptor activity leads to Decreased, Testosterone binding to androgen receptor (hypothalamus)
1143 T4 in serum, Decreased leads to Decreased, Thyroxine (T4) in tissues
1026 Inhibition, Deiodinase 2 leads to Decreased, Triiodothyronine (T3)
1037 Inhibition, Deiodinase 1 leads to Decreased, Triiodothyronine (T3)
2038 T4 in serum, Decreased leads to Decreased, Triiodothyronine (T3)
1163 Decreased, Thyroxine (T4) in tissues leads to Decreased, Triiodothyronine (T3) in tissues
1198 Inhibition, Deiodinase 1 leads to Decreased, Triiodothyronine (T3) in tissues
1199 Inhibition, Deiodinase 2 leads to Decreased, Triiodothyronine (T3) in tissues
330 Binding, VEGF-A leads to Decreased, VegfR2
333 Production, VEGF-A leads to Decreased, VegfR2
1382 Inhibition, Wnt pathway leads to Defect of Embryogenesis
905 Impaired, Proteostasis leads to Degeneration of dopaminergic neurons of the nigrostriatal pathway
906 Neuroinflammation leads to Degeneration of dopaminergic neurons of the nigrostriatal pathway
908 N/A, Mitochondrial dysfunction 1 leads to Degeneration of dopaminergic neurons of the nigrostriatal pathway
446 Down Regulation, K-Cl co-transporter 2 (KCC2) leads to Delay, Developmental GABA shift
2738 Increase, Vitellogenin mRNA leads to Delay, Ovarian maturation
1181 Depletion, energy reserves leads to Delayed, Sexual maturity
1173 Increased, valve movement leads to Depletion, energy reserves
1176 Increased, foot detachment leads to Depletion, energy reserves
1177 Increased, locomotion leads to Depletion, energy reserves
1218 Increase, cilia movement leads to Depletion, energy reserves
1219 increased or inappropriate, mantel display leads to Depletion, energy reserves
1228 Increased, muscular waves in foot leads to Depletion, energy reserves
168 N/A, Interferences with SH-/selen-proteins leads to Depletion, GSH
2877 Conjugation, Glutathione leads to Depletion, GSH
1673 Inhibition, mitochondrial DNA polymerase gamma (Pol gamma) leads to Depletion, mtDNA
2391 Altered, Meiotic chromosome dynamics leads to Ionizing Energy
658 Activation, Nicotinic acetylcholine receptor leads to Desensitization, Nicotinic acetylcholine receptor
1354 Activation of TGF-β signaling leads to Differentiation of Myofibroblast
972 Activation, AhR leads to dimerization, AHR/ARNT
2358 SARS-CoV-2 production leads to Diminished Protective Response to ROS
2360 Coagulation leads to Diminished Protective Response to ROS
2534 Binding to hERG channel leads to Direct hERG channel blockage
2535 hERG channel biogenesis interference leads to Direct hERG channel blockage
715 Disruption, Microtubule dynamics leads to Disorganization, Meiotic Spindle
2248 Binding, Transthyretin in serum leads to Displacement, Serum thyroxine (T4) from carrier protein
2250 Binding, Thyroid binding globulin in serum leads to Displacement, Serum thyroxine (T4) from carrier protein
2245 Binding, Transthyretin in serum leads to Displacement, Serum thyroxine (T4) from transthyretin
2477 Decreased, atRA concentration leads to Oocyte meiosis, disrupted
2605 Inhibit, voltage-gated sodium channel leads to Altered kinetics of sodium channel
2625 Altered kinetics of sodium channel leads to Disruption in action potential generation
1760 Decrease, Calcium currents leads to Disruption, Intracellular calcium mobilization
1678 Disturbance, Lysosomal function leads to Disruption, Lysosome
1775 endocytosis leads to Disruption, Lysosome
714 Binding, Tubulin leads to Disruption, Microtubule dynamics
60 Increase, Ca++ (intracellular) leads to Disruption, Mitochondrial electron transport chain
2561 Decreased, atRA concentration leads to Disruption, Progenitor cells of second heart field
1761 Disruption, Intracellular calcium mobilization leads to Disruption, Sarcomere assembly
1833 Binding of MSAs to microtubules leads to Disturbance in microtubule dynamic instability
837 Inhibition, Phospholipase A leads to Disturbance, Lysosomal function
1677 Binding of substrate, endocytic receptor leads to Disturbance, Lysosomal function
1634 Binding, topoisomerase II leads to DSB
1496 7α-hydroxypregnenolone synthesis in the brain, decreased leads to Dopamine release in the brain, decreased
519 Inhibition, FoxA2 leads to Down Regulation, CPT1A
240 Propagation, Oxidative stress leads to Down Regulation, Gulcose-6-phosphate dehydrogenase
523 Inhibition, FoxA2 leads to Down Regulation, HMGCS2
445 BDNF, Reduced leads to Down Regulation, K-Cl co-transporter 2 (KCC2)
2312 Binding to ACE2 leads to Downregulation of ACE2
1674 Depletion, mtDNA leads to Dysfunction, Mitochondria
1680 Alkylation, Protein leads to Dysfunction, Mitochondria
2672 Non-coding RNA expression,alteration leads to Dysfunctional autophagy
2296 Impaired gustatory nerve leads to taste impairment
2005 Increased Cholinergic Signaling leads to Cardiovascular dysregulation
2007 AchE Inhibition leads to Cardiovascular dysregulation
2311 Binding to ACE2 leads to ACE2 dysregulation
1855 Inflammatory events leads to Eczematous eruption
2675 Apoptosis leads to Emphysema
2676 Dysfunctional autophagy leads to Emphysema
2287 N/A, Neurodegeneration leads to Encephalitis
2288 Neuroinflammation leads to Encephalitis
2710 Increased, Intracellular Calcium overload leads to Endoplasmic reticulum stress
2452 Binding to ACE2 leads to Endothelial cell dysfunction
2510 SARS-CoV-2 cell entry leads to Endothelial cell dysfunction
2516 Pericyte dysfunction leads to Endothelial cell dysfunction
1928 Snail, Zeb, Twist activation leads to Epithelial-mesenchymal transition
2071 beta-catenin activation leads to Epithelial-mesenchymal transition
2669 Non-coding RNA expression,alteration leads to Epithelial-mesenchymal transition
2023 Increase of autoantibody production leads to Exacerbation of SLE
1272 Opening of calcium channel, Calcium influx leads to Sensory Airway Irritation
1355 Activation of TGF-β signaling leads to Expression of Collagen
1626 Differentiation of fibroblasts leads to Expression of Collagen
1627 EMT leads to Expression of Collagen
1722 Increase, Inflammation leads to Expression of Collagen
2438 six1b expression, increased leads to eya1 expression, inhibited
1804 Reduced collagen production leads to Smaller and morphologically distorted facial cartilage structures
2685 Decrease, sox9 expression leads to Smaller and morphologically distorted facial cartilage structures
2689 Activation, AhR leads to Smaller and morphologically distorted facial cartilage structures
2690 Increase, slincR expression leads to Smaller and morphologically distorted facial cartilage structures
1167 Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle leads to Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carbo
1168 Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failur leads to Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage)
1748 Decreased, PPARalpha transactivation of gene expression leads to Fatty Acid Beta Oxidation, Decreased
316 Altered, Transcription of genes by AR leads to Feminisation or incomplete development, Primary and accessory male sex organs
338 Alteration, Wnt pathway leads to Feminisation or incomplete development, Primary and accessory male sex organs
2355 Bradykinin, activated leads to Hypofibrinolysis
2670 Non-coding RNA expression,alteration leads to Fibroblast proliferation and differentiation
1839 Increase, Inflammation leads to Fibroproliferative airway lesions
1840 EMT leads to Fibroproliferative airway lesions
1592 Systemic cholesterol increased leads to Foam cell formation
1593 HDL-SAA formation leads to Foam cell formation
1848 Radical generation leads to DNA photo-adducts
1590 Systemic APR leads to HDL-SAA formation
1849 Radical generation leads to Protein photo-adducts
243 N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin leads to Formation, Formation of hemoglobin adducts
876 Activation, Long term AHR receptor driven direct and indirect gene expression changes leads to Formation, Hepatocellular and Bile duct tumors
997 Alterations, Cellular proliferation / hyperplasia leads to Formation, Hepatocellular and Bile duct tumors
859 Induction, Microvesicular fat leads to Formation, Liver fibrosis
860 Formation, Mallory body leads to Formation, Liver fibrosis
2898 Accumulation, Liver lipid leads to Formation, Liver fibrosis
298 Induction, Sustained Cell Proliferation leads to Formation, Liver tumor
2899 Formation, Liver fibrosis leads to Formation, Liver tumor
2900 Accumulation, Liver lipid leads to Formation, Liver tumor
852 Occurrence, Cytoplasmic vacuolization (hepatocyte) leads to Formation, Mallory body
854 Occurrence, Ballooning degeneration (hepatocyte) leads to Formation, Mallory body
856 Occurrence, Cytoplasmic vacuolization (Bile duct cell) leads to Formation, Mallory body
858 Occurrence, Cytoplasmic vacuolization (kupffer cell) leads to Formation, Mallory body
340 Activation, Pre-MIE: Metabolism of AFB1 leads to Formation, Pro-mutagenic DNA Adducts
402 Metabolism of AFB1, Production of Reactive Electrophiles leads to Formation, Pro-mutagenic DNA Adducts
2436 Repression of Gbx2 expression leads to foxi1 expression, increased
2450 Oxidative Stress leads to FOXJ1 Protein, Decreased
1924 Wnt ligand stimulation leads to Frizzled activation
2492 Recruitment of inflammatory cells leads to GI disorders
2494 Disruption of the intestinal barrier leads to GI disorders
1731 Lipid Peroxidation leads to General Apoptosis
1732 Unfolded Prortein Response leads to General Apoptosis
1285 Oxidization of biomolecules, Lipid bilayer and cellular proteins leads to Generation of novel epitopes , Antigen presentation
1291 Oxidation leads to Generation of novel epitopes , Antigen presentation
1576 TRPA1 activation, TRPA1 Receptor leads to Generation of novel epitopes , Antigen presentation
683 Reduction, Neuronal synaptic inhibition leads to Generation, Amplified excitatory postsynaptic potential (EPSP)
2417 Increased, DNA damage and mutation leads to Genomic instability
2531 Abnormal, Glucose homeostasis leads to GDM
1685 Oxidative Stress leads to Glutamate dyshomeostasis
1376 Down Regulation, GSS and GSTs gene leads to Glutathione homeostasis
1373 Down Regulation, GSS and GSTs gene leads to Glutathione synthesis
2273 Altered, Transcription of genes by AR leads to Reduced granulosa cell proliferation
1641 Reduced, Swimming performance leads to Growth, reduction
1925 Frizzled activation leads to GSK3beta inactivation
2532 ACE2 dysregulation leads to Gut dysbiosis
2543 Recruitment of inflammatory cells leads to Gut dysbiosis
1759 Decrease, Cardiac ejection fraction leads to Heart failure
2521 Hyperactivation of ACE/Ang-II/AT1R axis leads to Heart failure
2824 Decrease, Cardiac contractility leads to Heart failure
1548 Reduced, mucosal defense leads to Helicobacter pylori infection
1165 Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carbo leads to Hemostasis, Depletion from blood of fully functional carboxylated clotting factors
1513 Oxidative Stress leads to Hepatocytotoxicity
1515 Activation of Cyp2E1 leads to Hepatocytotoxicity
1377 Perturbation of cholesterol leads to Hepatotoxicity
1378 Glutathione homeostasis leads to Hepatotoxicity
747 Hippocampal gene expression, Altered leads to Hippocampal anatomy, Altered
1388 T4 in serum, Decreased leads to Hippocampal anatomy, Altered
746 T4 in neuronal tissue, Decreased leads to Hippocampal gene expression, Altered
1387 T4 in serum, Decreased leads to Hippocampal gene expression, Altered
1947 TR Antagnoism leads to Hippocampal gene expression, Altered
749 Hippocampal anatomy, Altered leads to Hippocampal Physiology, Altered
1389 T4 in serum, Decreased leads to Hippocampal Physiology, Altered
2863 Increase, Cell death leads to Hippocampal Physiology, Altered
2875 Cell injury/death leads to Hippocampal Physiology, Altered
2886 Hippocampal gene expression, Altered leads to Hippocampal Physiology, Altered
1709 Histone deacetylase inhibition leads to Histone acetylation, increase
2698 Increased S1-P leads to Histone deacetylase inhibition
2520 Induced, Angiotensin (Ang) II accumulation leads to Hyperactivation of ACE/Ang-II/AT1R axis
2354 Recruitment of inflammatory cells leads to Hyperinflammation
2357 Bradykinin, activated leads to Hyperinflammation
2414 inflammasome activity, increased leads to Hyperinflammation
2495 Disruption of the intestinal barrier leads to Hyperinflammation
2505 Oxidative Stress leads to p-Tau
69 Proliferation, Cell proliferation in the absence of cytotoxicity leads to Hyperplasia, Hyperplasia
398 Increase proliferation, Leydig cell leads to Hyperplasia, Leydig cell
1113 Increased, circulating estrogen levels leads to Hyperplasia, Mammary gland
1114 Increased, prolactin exposure leads to Hyperplasia, Mammary gland
1091 Increased, secrection of FSH from anterior pituitary leads to Hyperplasia, ovarian epithelium
2585 Increased, circulating estrogen levels leads to Hyperplasia, ovarian epithelium
1090 Increased, secrection of FSH from anterior pituitary leads to Hyperplasia, ovarian stromal cells
1092 Increased, secretion of LH from anterior pituitary leads to Hyperplasia, ovarian stromal cells
2584 Increased, circulating estrogen levels leads to Hyperplasia, ovarian stromal cells
758 Increased, Chloride conductance leads to hyperpolarisation, neuron
1565 Opening of GIRK channels leads to hyperpolarisation, neuron
989 Goblet cell hyperplasia leads to Hypersecretion, Mucus
990 Goblet cell metaplasia leads to Hypersecretion, Mucus
991 Increase, Mucin production leads to Hypersecretion, Mucus
983 Increase, Vascular Resistance leads to Hypertension
1082 Proliferation/Clonal Expansion, smooth muscle leads to Hypertrophy/hyperplasia, smooth muscle
2828 Decrease, AR activation leads to Hypospadias
2196 Immune cell activation leads to IFNγ signaling
2317 Increased AngII leads to Sodium inhibition, Sweet enhancement
2194 Reactive Metabolite leads to Immune cell activation
2199 Increase in inflammation leads to hepatitis
1277 Non-neuronal production of TNF, Epithelial irritation leads to Leukocyte infiltration
1577 SP (Substance P) release, Local increase of SP leads to Leukocyte infiltration
1585 Increased NKA leads to Leukocyte infiltration
1586 Increased CGRP leads to Leukocyte infiltration
1922 Impaired T cell activation leads to Impaired Ab production
1819 Suppressed DC activation leads to Impaired antigen presentation
1834 Disturbance in microtubule dynamic instability leads to Impaired axonial transport
2503 Accumulation, Toxic Tau oligomers leads to Impaired axonial transport
2011 Increased Cholinergic Signaling leads to Impaired coordination and movement
2014 AchE Inhibition leads to Impaired coordination and movement
127 Agonism, Estrogen receptor leads to Impaired development of, Reproductive organs
2295 Induced, Angiotensin (Ang) II accumulation leads to Impaired gustatory nerve
2298 Increased AngII leads to Impaired gustatory nerve
2301 Increased proinflammatory mediators leads to Impaired gustatory nerve
2318 Sodium inhibition, Sweet enhancement leads to Impaired gustatory nerve
1813 Blocking of IL-1R leads to Impaired IL-1 signaling
1814 Decreased IL-1 production leads to Impaired IL-1 signaling
1937 Decrease, AR activation leads to Impaired inguinoscrotal phase
2905 Mitochondrial dysfunction leads to Impaired insulin signaling
2906 Increased, Oxidative Stress leads to Impaired insulin signaling
2257 Reduced tidal volume leads to Impaired lung function
2258 Loss of alveolar capillary membrane integrity leads to Impaired lung function
2285 Alveolar collapse leads to Impaired lung function
2514 Heart failure leads to Altered mechanotransduction properties of pericytes
2364 Olfactory epithelium degeneration leads to anosmia
2365 Sustentacular cells, decrease leads to anosmia
2366 olfacotry neurons, decrease leads to anosmia
1989 Reduction, progesterone uptake, decresed maturation leads to Impaired ovulation
1975 Reduced tidal volume leads to Impaired oxygenation of the blood
1171 Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction leads to Impaired recruitment , Population trajectory
1820 Impaired antigen presentation leads to Impaired T cell activation
1921 Inhibition, Nuclear factor kappa B (NF-kB) leads to Impaired T cell activation
571 Increased, Viral susceptibility leads to impaired, Development
394 irregularities, ovarian cycle leads to impaired, Fertility
405 Malformation, Male reproductive tract leads to impaired, Fertility
462 Hyperplasia, Leydig cell leads to impaired, Fertility
1650 Decreased sperm quantity or quality in the adult, Decreased fertility leads to impaired, Fertility
2161 Decreased spermatogenesis leads to impaired, Fertility
2274 Impaired, Spermatogenesis leads to impaired, Fertility
2293 decreased oocyte maturation leads to impaired, Fertility
2386 Increase, Oocyte apoptosis leads to impaired, Fertility
2394 Ionizing Energy leads to impaired, Fertility
2487 Ovarian follicle pool, reduced leads to impaired, Fertility
2879 Increase, LPO leads to impaired, Fertility
573 Decrease, Number of worker bees leads to impaired, Hive thermoregulation
665 impaired, Thoracic shivering leads to impaired, Hive thermoregulation
1152 N/A, Mitochondrial dysfunction 1 leads to impaired, Hive thermoregulation
562 Reduced, Food storage leads to impaired, Larval development
566 Reduced, Brood care leads to impaired, Larval development
2631 Decreased, Maturation Inducing Steroids Surge by Granulosa cells leads to Impaired, Oocyte maturation and ovulation
904 N/A, Mitochondrial dysfunction 1 leads to Impaired, Proteostasis
1942 Mitochondrial Injury leads to Impaired, Proteostasis
2633 Increased, Oocyte Atresia leads to Impaired, Reproduction
2730 Activation, estrogen receptor alpha leads to Impaired, Reproduction
2076 Decreased, 11KT leads to Impaired, Spermatogenesis
664 N/A, Mitochondrial dysfunction 1 leads to impaired, Thoracic shivering
1961 dysfunction of microcirculation leads to anterior-posterior axis development
2027 Suppression of IL-4 production leads to Impairment, TDAR
1022 Reduction, NFAT/AP-1 complex formation leads to Impairment of TDAR
1259 Suppression, Suppression of T-cell dependent antibody production leads to Impairment of TDAR
1260 Suppression, Suppression of production of cytotoxic T-cells leads to Impairment of TDAR
1822 Impaired T cell activation leads to Impairment of TDAR
1823 Suppression, Suppression of T-cell dependent antibody response (TDAR) leads to Impairment of TDAR
1826 Suppressed MyD88 leads to Impairment of TDAR
1871 Inhibition, Nuclear factor kappa B (NF-kB) leads to Impairment of TDAR
1923 Impaired Ab production leads to Impairment of TDAR
2004 Suppression of T cell activation leads to Impairment of TDAR
36 Reduction, Angiogenesis leads to Impairment, Endothelial network
975 reduced production, VEGF leads to Impairment, Endothelial network
62 Decreased, Calcium influx leads to Impairment, Learning and memory
214 Inhibition, NMDARs leads to Impairment, Learning and memory
228 Binding of antagonist, NMDA receptors leads to Impairment, Learning and memory
359 Neuronal network function, Decreased leads to Impairment, Learning and memory
634 Decreased, Neuronal network function in adult brain leads to Impairment, Learning and memory
1069 N/A, Neurodegeneration leads to Impairment, Learning and memory
1146 Activation, Nicotinic acetylcholine receptor leads to Impairment, Learning and memory
1310 Altered, Ca2+-calmodulin activated signal transduction leads to Impairment, Learning and memory
1503 Inhibition, Na+/I- symporter (NIS) leads to Impairment, Learning and memory
1506 TH synthesis, Decreased leads to Impairment, Learning and memory
1507 BDNF, Reduced leads to Impairment, Learning and memory
1643 Decrease, histaminergic neuron excitation leads to Impairment, Learning and memory
2808 Dysfunctional synapses leads to Impairment, Learning and memory
2836 Increase, Neural Remodeling leads to Impairment, Learning and memory
2838 Energy Deposition leads to Impairment, Learning and memory
2839 Increase, Pro-Inflammatory Mediators leads to Impairment, Learning and memory
2864 Hippocampal Physiology, Altered leads to Impairment, Learning and memory
1020 Reduction, NFAT/AP-1 complex formation leads to Impairment, T-cell dependent antibody response
1258 Suppression, Suppression of production of cytotoxic T-cells leads to Impairment, T-cell dependent antibody response
1510 Suppression, IL-2 and IL-4 production leads to Impairment, T-cell dependent antibody response
1436 Decreased, extracellular serotonin leads to Inactivated, 5-HTR
1465 Increased, intracellular chloride (Cl-) leads to Inactive, membrane depolarization
24 Alkylation, DNA leads to Inadequate DNA repair
1909 Increase, Oxidative DNA damage leads to Inadequate DNA repair
1911 Increase, DNA strand breaks leads to Inadequate DNA repair
2398 Bulky DNA adducts, increase leads to Inadequate DNA repair
2608 Increased, DNA damage and mutation leads to Inadequate DNA repair
1792 DNA DNA double strand breaks leads to DNA repair
1237 Peptide Oxidation leads to Increase activation, Nuclear factor kappa B (NF-kB)
2308 Increase, ROS production leads to Increase activation, Nuclear factor kappa B (NF-kB)
2320 Increased, Reactive oxygen species leads to Increase activation, Nuclear factor kappa B (NF-kB)
2430 MyD88 activation leads to Increase activation, Nuclear factor kappa B (NF-kB)
2611 Decrease,SIRT1(sirtuin 1) levels leads to Increase activation, Nuclear factor kappa B (NF-kB)
1795 Increase mutations leads to Increase cell proliferation
1796 Increase chromosomal aberrations leads to Increase cell proliferation
1794 DNA repair leads to Increase chromosomal aberrations
1799 Ionizing Energy leads to Increase chromosomal aberrations
2728 Increased, DNA damage and mutation leads to Increase chromosomal aberrations
1791 Ionizing Energy leads to DNA DNA double strand breaks
2197 IFNγ signaling leads to Increase in inflammation
2198 Apoptotic cell death leads to Increase in inflammation
2644 Inhibition, Nuclear factor kappa B (NF-kB) leads to Increase in inflammation
1903 Increased pro-inflammatory mediators leads to Increase in RONS
1905 Leukocyte recruitment/activation leads to Increase in RONS
2330 Excitation of intracellular water leads to Increase in RONS
2616 Energy Deposition leads to Increase in RONS
1793 DNA repair leads to Increase mutations
1798 Ionizing Energy leads to Increase mutations
1899 Increase, DNA Damage leads to Increase mutations
2022 Increase of Th2 cells producing IL-4 leads to Increase of autoantibody production
2021 Induction of GATA3 expression leads to Increase of Th2 cells producing IL-4
2798 Increase in RONS leads to methemocyanin formation (decrease overall oxygen binding capacity)
2066 Increased AngII leads to Increase plasma Ang II
2136 Downregulation of ACE2 leads to Increase plasma Ang II
2434 ACE2 enzymatic inhibition leads to Increase plasma Ang II
461 Increase, Luteinizing hormone (LH) leads to Increase proliferation, Leydig cell
2602 Increase, Apoptosis leads to Microcephaly
2603 Altered differentiation leads to Microcephaly
2604 Energy Deposition leads to Microcephaly
2607 Premature differentiation leads to Microcephaly
2750 Increase, Incomplete ecdysis leads to Increase, delay in oviposition
2746 Increase, Defects in tanning of new cuticle leads to Increase, impairment of cuticle sclerotization
2747 Increase, Defects in tanning of new cuticle leads to Increase, pigmentation
2090 Increase, Protein oxidation leads to Increase, Abnormal osmoregulation
2180 Decrease, ATPase activity leads to Increase, Abnormal osmoregulation
728 Increase, Hyperplasia (terminal bronchiolar cells) leads to Increase, Adenomas/carcinomas (bronchioloalveolar)
743 Increase, Hyperplasia (follicular cells) leads to Increase, Adenomas/carcinomas (follicular cell)
2426 Increased, Hyperplasia (follicular cells) leads to Increase, Adenomas/carcinomas (follicular cell)
761 Increase, Hyperplasia (renal tubular cells) leads to Increase, Adenomas/carcinomas (renal tubular)
786 Increase, Hyperplasia (tubular epithelial cells) leads to Increase, Adenomas/carcinomas (renal tubular)
798 Increase, Hyperplasia (urothelial) leads to Increase, Adenomas/carcinomas (urothelial)
1701 Activation/Proliferation, T-cells leads to Increase, Allergic Respiratory Hypersensitivity Response
2650 Covalent Binding, Protein leads to Increase, Allergic Respiratory Hypersensitivity Response
1546 Helicobacter pylori infection leads to Increase, ammonium (NH4+)
723 Altered, Chromosome number leads to Increase, Aneuploid offspring
1479 Activation, PTGS-2 leads to Increase, angiogenesis
2574 Increase, Inflammation leads to Increase, angiogenesis
2575 Increased, Migration (Endothelial Cells) leads to Increase, angiogenesis
1468 Increase, DNA Damage leads to Increase, Apoptosis
1750 Decrease, Mitochondrial ATP production leads to Increase, Apoptosis
1877 Increase,Oxidative DNA damage leads to Increase, Apoptosis
2074 Increase, DNA strand breaks leads to Increase, Apoptosis
2088 Increase, DNA DSB leads to Increase, Apoptosis
2184 Increase, Cyt c release leads to Increase, Apoptosis
2187 Increase, ROS production leads to Increase, Apoptosis
2210 Increase, LPO leads to Increase, Apoptosis
2226 Increase, Global methylation leads to Increase, Apoptosis
2600 Activation of TP53 leads to Increase, Apoptosis
2618 Increased, Oxidative Stress leads to Increase, Apoptosis
2640 Increase, Mt Dysfunction leads to Increase, Apoptosis
2643 ER stress leads to Increase, Apoptosis
2723 Decrease, GLI1/2 target gene expression leads to Increase, Apoptosis
2733 Decrease, SHH second messenger production leads to Increase, Apoptosis
1483 Activation, PTGS-1 leads to Increase, bicarbonate
1206 Increased, Hepatic thyroid hormone uptake/transport leads to Increase, Biliary excretion TH glucuronide
2235 Induction, Upregulation of glucuronyltransferase activity leads to Increase, Biliary excretion TH glucuronide
2091 Increase, Abnormal osmoregulation leads to Increase, Body fluid overload
2739 Delay, Ovarian maturation leads to Increase, Body volume of female adults
2844 Altered Bone Cell Homeostasis leads to Bone Remodeling
2848 Energy Deposition leads to Bone Remodeling
61 Inhibition, Ca++ ATPase leads to Increase, Ca++ (intracellular)
899 Increase, Mutations leads to Increase, Cancer
901 Alkylation, DNA leads to Increase, Cancer
2102 Decrease, Global DNA methylation leads to Increase, Casp transcription
2109 Increase, DNA DSB leads to Increase, Casp transcription
2111 Decrease, Heritable DNA methylation (F3) leads to Increase, Casp transcription (F3)
2214 Decrease, ATP pool leads to Increase, Cell death
2221 Increase,Oxidative DNA damage leads to Increase, Cell death
2222 Increase, LPO leads to Increase, Cell death
2223 Increase, Protein oxidation leads to Increase, Cell death
2439 eya1 expression, inhibited leads to Increase, Cell death
2488 SARS-CoV-2 production leads to Increase, Cell death
2705 Activation, calpain leads to Increase, Cell death
2712 Unfolded Prortein Response leads to Increase, Cell death
2715 Mitochondrial Injury leads to Increase, Cell death
2716 Oxidative Stress leads to Increase, Cell death
2717 Neuroinflammation leads to Increase, Cell death
2764 Increase, Cytosolic Ca leads to Increase, Cell death
2873 decreased, Bcl-2 expression leads to Increase, Cell death
2874 increased, Bax expression leads to Increase, Cell death
1745 Increase, SUR binding leads to Increase, Cell membrane depolarization
2707 Inhibition, GABAAr leads to Increase, Cell membrane depolarization
2787 Decreased Na/K ATPase activity leads to Increase, Cell membrane depolarization
889 Increase, Respiratory or Squamous Metaplasia leads to Increase, Cell Proliferation
1966 Increased, DNA damage and mutation leads to Increase, Cell Proliferation
1978 Increase, Mutations leads to Increase, Cell Proliferation
1979 Increase, Chromosomal aberrations leads to Increase, Cell Proliferation
2418 Genomic instability leads to Increase, Cell Proliferation
2814 Energy Deposition leads to Increase, Cell Proliferation
1250 Increased, ER binding to DNA (classical pathway) leads to Increase, Cell Proliferation (Epithelial Cells)
1251 Increased, ER binding to T.F. to DNA (non-classical pathway) leads to Increase, Cell Proliferation (Epithelial Cells)
1896 Increase, Mutations leads to Increase, Cell Proliferation (Epithelial Cells)
1900 Increase mutations leads to Increase, Cell Proliferation (Epithelial Cells)
1901 Leukocyte recruitment/activation leads to Increase, Cell Proliferation (Epithelial Cells)
1908 Increased pro-inflammatory mediators leads to Increase, Cell Proliferation (Epithelial Cells)
711 Activation, Constitutive androstane receptor leads to Increase, cell proliferation (hepatocytes)
787 Activation, Androgen receptor leads to Increase, cell proliferation (hepatocytes)
1230 Increase, Phenotypic enzyme activity leads to Increase, cell proliferation (hepatocytes)
1269 Altered expression of hepatic CAR-dependent genes leads to Increase, cell proliferation (hepatocytes)
2252 Activation, PPARα leads to Increase, cell proliferation (hepatocytes)
1912 Inadequate DNA repair leads to Increase, Chromosomal aberrations
1939 Increase, DNA strand breaks leads to Increase, Chromosomal aberrations
1982 Energy Deposition leads to Increase, Chromosomal aberrations
636 Increased, serotonin (5-HT) 1 leads to Increase, cilia movement
1318 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to Increase, cilia movement
1333 Increased, serotonin (5-HT) leads to Increase, cilia movement
1231 Increase, Phenotypic enzyme activity leads to Increase, Clonal Expansion of Altered Hepatic Foci
1239 Increase, cell proliferation (hepatocytes) leads to Increase, Clonal Expansion of Altered Hepatic Foci
1350 dimerization, AHR/ARNT leads to Increase, COX-2 expression
2077 Activation, Glucocorticoid Receptor leads to Increase, Cripto-1 expression
2183 Increase, Complex III dysfunction leads to Increase, Cyt c release
2763 Decrease, Coupling of OXPHOS leads to Increase, Cytosolic Ca
1401 Activation, L-FABP leads to Increase, cytosolic fatty acid
1405 Increased, lipogenesis leads to Increase, cytosolic fatty acid
1692 Inhibition of fatty acid beta oxidation leads to Increase, cytosolic fatty acid
765 Peptide Oxidation leads to Increase, Cytotoxicity
886 Decrease, Intracellular pH leads to Increase, Cytotoxicity
776 Increased, Plasma tyrosine leads to Increase, Cytotoxicity (corneal cells)
2658 Recruitment of inflammatory cells leads to Increase, Cytotoxicity (epithelial cells)
707 Increased, Accumulation of alpha2u microglobulin (proximal tubular epithelium) leads to Increase, Cytotoxicity (renal tubular cell)
1675 Dysfunction, Mitochondria leads to Increase, Cytotoxicity (renal tubular cell)
1679 Disruption, Lysosome leads to Increase, Cytotoxicity (renal tubular cell)
1682 Decrease, Mitochondrial ATP production leads to Increase, Cytotoxicity (renal tubular cell)
2567 Increase, Mt Dysfunction leads to Increase, Cytotoxicity (renal tubular cell)
795 Increase, Urinary bladder calculi leads to Increase, Cytotoxicity (urothelial cells)
2331 Increase in RONS leads to D1 protein deactivation
2342 Increase, ROS leads to D1 protein deactivation
2348 Increase, ROS production leads to D1 protein deactivation
2549 Increased, Reactive oxygen species leads to D1 protein deactivation
2745 Decrease, dopa decarboxylase leads to Increase, Defects in tanning of new cuticle
2741 Increase, Body volume of female adults leads to Increase, developmental abnormalities
2742 Increase, sex ratio (F/M) leads to Increase, developmental abnormalities
2759 Increase, Incomplete ecdysis leads to Increase, developmental abnormalities
1624 Increased, secretion of local growth factors leads to Differentiation of fibroblasts
1633 Sustained inflammatory cytokine release leads to Differentiation of fibroblasts
1652 TGFbeta pathway activation leads to Differentiation of fibroblasts
1300 Increased, Oxidative Stress leads to Increase, DNA Damage
1467 Peptide Oxidation leads to Increase, DNA Damage
1595 Increase, ROS leads to Increase, DNA Damage
1602 Increase, ROS production leads to Increase, DNA Damage
1904 Increase in RONS leads to Increase, DNA Damage
2380 Ionizing Energy leads to Increase, DNA Damage
2552 Energy Deposition leads to Increase, DNA Damage
2087 Increase, Formation of DNA photoproducts leads to Increase, DNA DSB
2100 Increase,Oxidative DNA damage leads to Increase, DNA DSB
2108 Increase, DNMT inhibition leads to Increase, DNA DSB
1883 Increase, DNMT inhibition leads to Increase, DNA hypomethylation
1930 Increase, SAM depletion leads to Increase, DNA hypomethylation
1992 Activation, AhR leads to Increase, DNMT expression
1996 dimerization, AHR/ARNT leads to Increase, DNMT expression
1910 Inadequate DNA repair leads to Increase, DNA strand breaks
1913 Increase, Oxidative DNA damage leads to Increase, DNA strand breaks
1977 Energy Deposition leads to Increase, DNA strand breaks
2811 Oxidative Stress leads to Increase, DNA strand breaks
984 Activation, AhR leads to Increase, Early Life Stage Mortality
1567 Altered, Cardiovascular development/function leads to Increase, Early Life Stage Mortality
2686 Smaller and morphologically distorted facial cartilage structures leads to Increase, Early Life Stage Mortality
770 Increase, Dopaminergic activity leads to Increase, Endometrial adenocarcinomas
771 Increase, Hyperplasia (glandular epithelial cells of endometrium) leads to Increase, Endometrial adenocarcinomas
2775 Altered Signaling leads to Increase, Endothelial Dysfunction
2776 Oxidative Stress leads to Increase, Endothelial Dysfunction
2777 Increased pro-inflammatory mediators leads to Increase, Endothelial Dysfunction
2780 Energy Deposition leads to Increase, Endothelial Dysfunction
2789 Altered, Nitric Oxide Levels leads to Increase, Endothelial Dysfunction
66 Up Regulation, CD36 leads to Increase, FA Influx
1415 Activation, HSD17B4 leads to Increase, Fatty acid β-oxidation
2216 Decrease, ATP pool leads to Increase, Fatty acid β-oxidation
1596 Increase, Apoptosis leads to Increase, Follicular atresia
2587 Increase, DNA strand breaks leads to Increase, Follicular atresia
2591 Increase, Oxidative DNA damage leads to Increase, Follicular atresia
1344 Increase, E75b expression leads to Increase, Ftz-f1 expression
1461 Activate, presynaptic neuron 2 leads to Increase, GABA
1884 Increase, DNA hypomethylation leads to Increase, Gene expression
1888 Decrease, Transgenerational DNA methylation leads to Increase, Gene expression
1233 Activation, PPARα leads to Increase, Genes involved in fatty acid oxidation
2225 Increase, ROS production leads to Increase, Global methylation
2884 Induction, Upregulation of glucuronyltransferase activity leads to Increase, Glucuronidation of T4
2793 Decrease, Coupling of OXPHOS leads to Increase, Glycolysis
2857 Activation, EGFR leads to Increase, goblet cell number
1672 Decrease, Leaf development leads to Increase, Growth hormone
2803 Decrease overall oxygen binding capacity (methemocyanin formation) leads to Increase, hemocyanin mRNA
764 Peptide Oxidation leads to Increase, hepatocellular adenomas and carcinomas
766 Increase, Cytotoxicity leads to Increase, hepatocellular adenomas and carcinomas
774 Increase, Preneoplastic foci (hepatocytes) leads to Increase, hepatocellular adenomas and carcinomas
1232 Increase, Clonal Expansion of Altered Hepatic Foci leads to Increase, hepatocellular adenomas and carcinomas
2253 Activation, PPARα leads to Increase, hepatocellular adenomas and carcinomas
2254 Increase, cell proliferation (hepatocytes) leads to Increase, hepatocellular adenomas and carcinomas
23 Alkylation, DNA leads to Increase, Heritable mutations in offspring
202 Increase, Mutations leads to Increase, Heritable mutations in offspring
1993 Increase, DNMT expression leads to Increase, hypermethylation of the promotor region of GnRHR
742 Increase, Hypertrophy and proliferation (follicular cell) leads to Increase, Hyperplasia (follicular cells)
2427 Increased, Hypertrophy and proliferation (follicular cell) leads to Increase, Hyperplasia (follicular cells)
782 Increase, Regenerative cell proliferation (forestomach epithelial cells) leads to Increase, Hyperplasia (forestomach epithelial cells)
772 Decreased, Progesterone from corpus luteum leads to Increase, Hyperplasia (glandular epithelial cells of endometrium)
730 Decreased, Testosterone binding to androgen receptor (hypothalamus) leads to Increase, Hyperplasia (Leydig cells)
745 Increased, Luteinizing hormone (LH) leads to Increase, Hyperplasia (Leydig cells)
794 Increased, Leutinizing hormone (LH) leads to Increase, Hyperplasia (Leydig cells)
760 Increase, Regenerative cell proliferation (tubular epithelial cells) leads to Increase, Hyperplasia (renal tubular cells)
727 Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells) leads to Increase, Hyperplasia (terminal bronchiolar cells)
785 Increase, Regenerative cell proliferation (tubular epithelial cells) leads to Increase, Hyperplasia (tubular epithelial cells)
797 Increase, Regenerative cell proliferation (urothelial cells) leads to Increase, Hyperplasia (urothelial)
1444 Increase, vascular smooth muscle contraction leads to Increase, hypertension
1580 Increased CGRP leads to Increase, hypertension
741 Increase, Thyroid-stimulating hormone (TSH) leads to Increase, Hypertrophy and proliferation (follicular cell)
2424 Increased, Thyroid-stimulating hormone (TSH) leads to Increase, Hypertrophy and proliferation (follicular cell)
2017 Stimulation of TLR7/8 leads to Increase of IL-23
1000 Decrease, Circulating ETH leads to Increase, Incomplete ecdysis
1001 Decreased, synthesis and secretion of molting fluid proteases leads to Increase, Incomplete ecdysis
1010 Decrease, Abdominal muscle contraction leads to Increase, Incomplete ecdysis
1011 Decrease, Digestion of old cuticle leads to Increase, Incomplete ecdysis
2748 Increase, impairment of cuticle sclerotization leads to Increase, Incomplete ecdysis
2749 Increase, pigmentation leads to Increase, Incomplete ecdysis
2758 Decrease, New cuticle secretion leads to Increase, Incomplete ecdysis
108 Release, Cytokine leads to Increase, Inflammation
780 Increase, Cytotoxicity (epithelial cells) leads to Increase, Inflammation
1720 Activation of PPARγ leads to Increase, Inflammation
1721 Activation of TGF-β signaling leads to Increase, Inflammation
1838 Airway epithelial injury leads to Increase, Inflammation
2568 Activation, AhR leads to Increase, Inflammation
777 Increase, Cytotoxicity (corneal cells) leads to Increase, Inflammation (corneal cells)
1439 Activate, PLC leads to Increase, inositol triphosphate
1440 Increase, inositol triphosphate leads to Increase, intracellular calcium
731 Increase, Hyperplasia (Leydig cells) leads to Increase, Leydig cell tumors
1598 Increase, ROS leads to Increase, LPO
1603 Increase, ROS production leads to Increase, LPO
2460 Increased, Reactive oxygen species leads to Increase, LPO
277 Damaging, Red blood cells; hemolysis leads to Increase, Liver and splenic hemosiderosis
1797 Increase cell proliferation leads to Increase, lung cancer
1800 Increase mutations leads to Increase, lung cancer
1801 Increase chromosomal aberrations leads to Increase, lung cancer
1980 Increase, Cell Proliferation leads to Increase, lung cancer
1983 Energy Deposition leads to Increase, lung cancer
1984 Increase, Mutations leads to Increase, lung cancer
1985 Increase, Chromosomal aberrations leads to Increase, lung cancer
460 Reduction, testosterone level leads to Increase, Luteinizing hormone (LH)
2188 Decrease, Coupling of OXPHOS leads to Increase, Complex I dysfunction
1944 Binding of inhibitor, mitochondrial complex III leads to Increase, Mitochondrial complex III antagonism
2182 Decrease, Coupling of OXPHOS leads to Increase, Complex III dysfunction
2564 Inhibition, ETC complexes of the respiratory chain leads to Increase, Mt Dysfunction
2566 Increase, Oxidative Stress leads to Increase, Mt Dysfunction
2637 Decrease, MMP leads to Increase, Mt Dysfunction
2796 Decrease, Coupling of OXPHOS leads to Increase, Mitochondrial swelling
262 Induction, Pre-mature molting leads to Increase, Mortality
1002 Increase, Incomplete ecdysis leads to Increase, Mortality
1352 Altered, Cardiovascular development/function leads to Increase, Mortality
1744 Increase, Premature molting leads to Increase, Mortality
1751 Increase, Apoptosis leads to Increase, Mortality
1874 Increase, Necrosis leads to Increase, Mortality
2092 Increase, Body fluid overload leads to Increase, Mortality
2096 Decrease, ATP pool leads to Increase, Mortality
2462 Increased, Kidney Failure leads to Increase, Mortality
2743 Increase, developmental abnormalities leads to Increase, Mortality
2825 Heart failure leads to Increase, Mortality
986 Activation, EGFR leads to Increase, Mucin production
987 Activation, Sp1 leads to Increase, Mucin production
1312 Goblet cell hyperplasia leads to Increase, Mucin production
1313 Goblet cell metaplasia leads to Increase, Mucin production
2858 Increase, goblet cell number leads to Increase, Mucin production
1481 Activation, PTGS-1 leads to Increase, mucosal blood flow
1482 Activation, PTGS-1 leads to Increase, mucous
25 Alkylation, DNA leads to Increase, Mutations
164 Inadequate DNA repair leads to Increase, Mutations
1897 Increase, DNA Damage leads to Increase, Mutations
1907 Increase, Cell Proliferation (Epithelial Cells) leads to Increase, Mutations
1914 Increase, Oxidative DNA damage leads to Increase, Mutations
1931 Increase, DNA strand breaks leads to Increase, Mutations
1981 Energy Deposition leads to Increase, Mutations
2399 Bulky DNA adducts, increase leads to Increase, Mutations
893 Increase, Cell Proliferation leads to Increase, Mutations in Critical Genes
1442 Activate, calmodulin leads to Increase, myosin light chain phosphorylation
1873 Decrease, Mitochondrial ATP production leads to Increase, Necrosis
2121 Decrease, ATP pool leads to Increase, Necrosis
2464 Increase, LPO leads to Increase, Necrosis
767 Increase, Cytotoxicity (club cells) leads to Increase, Necrosis (terminal bronchiolar cells)
2835 Increase, Pro-Inflammatory Mediators leads to Increase, Neural Remodeling
2837 Energy Deposition leads to Increase, Neural Remodeling
2840 Altered Signaling leads to Increase, Neural Remodeling
2841 Increase, DNA strand breaks leads to Increase, Neural Remodeling
1343 Increase, EcR agonism leads to Increase, E75b expression
2103 Increase, Casp transcription leads to Increase, Oocyte apoptosis
2120 Decrease, ATP pool leads to Increase, Oocyte apoptosis
2382 Increase, DNA Damage leads to Increase, Oocyte apoptosis
2383 Altered, Meiotic chromosome dynamics leads to Increase, Oocyte apoptosis
2385 Increased, Oxidative Stress leads to Increase, Oocyte apoptosis
2397 Ionizing Energy leads to Increase, Oocyte apoptosis
2558 Increase,Oxidative DNA damage leads to Increase, Oocyte apoptosis
2589 Increase, DNA strand breaks leads to Increase, Oocyte apoptosis
2592 Increase, Oxidative DNA damage leads to Increase, Oocyte apoptosis
2112 Increase, Casp transcription (F3) leads to Increase, Oocyte apoptosis (F3)
1746 Increase, Cell membrane depolarization leads to Increase, Opening of voltage-dependent calcium channel
2106 Increase, Ovarian somatic cell apoptosis leads to Increase, Ovarian follicle breakdown
2122 Increase, Necrosis leads to Increase, Ovarian follicle breakdown
2117 Increase, Ovarian somatic cell apoptosis (F3) leads to Increase, Ovarian follicle breakdown (F3)
2105 Increase, Casp transcription leads to Increase, Ovarian somatic cell apoptosis
2559 Increase,Oxidative DNA damage leads to Increase, Ovarian somatic cell apoptosis
2116 Increase, Casp transcription (F3) leads to Increase, Ovarian somatic cell apoptosis (F3)
2590 Increase, ROS production leads to Increase, Oxidative DNA damage
2810 Oxidative Stress leads to Increase, Oxidative DNA damage
2813 Energy Deposition leads to Increase, Oxidative DNA damage
1876 Increase, ROS leads to Increase,Oxidative DNA damage
2099 Increase, ROS production leads to Increase,Oxidative DNA damage
762 Increased, Induction of pyruvate dehydrogenase (PDH) leads to Increase, Oxidative metabolism
2565 Inhibition, ETC complexes of the respiratory chain leads to Increase, Oxidative Stress
2895 SDH, inhibited leads to Increase, Oxidative Stress
2896 Superoxide generation, increased leads to Increase, Oxidative Stress
1361 ROS formation leads to Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK
2219 Decrease, Coupling of OXPHOS leads to Increase, Oxygen consumption
779 Increase, Regenerative cell proliferation (corneal cells) leads to Increase, Papillomas/carcinomas (squamous cells)
783 Increase, Hyperplasia (forestomach epithelial cells) leads to Increase, Papillomas/carcinomas (squamous cells)
977 Altered, Cardiovascular development/function leads to Increase, Pericardial edema
1240 Increase, Genes involved in fatty acid oxidation leads to Increase, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids
1229 Activation, PPARα leads to Increase, Phenotypic enzyme activity
1238 Increase activation, Nuclear factor kappa B (NF-kB) leads to Increase, Phenotypic enzyme activity
2408 abnormal, placental labyrinth vasculature morphology leads to increase, placental insufficiency
336 Increase, Vitellogenin synthesis in liver leads to Increase, Plasma vitellogenin concentrations
1480 Activation, PTGS-1 leads to Increase, platelet aggregation
2554 Altered, Meiotic chromosome dynamics leads to Increase, Pollen abnormal
638 Increased, locomotion leads to Increase, predation
1183 Increased, foot detachment leads to Increase, predation
1185 Depletion, energy reserves leads to Increase, predation
1227 Increased, valve movement leads to Increase, predation
2409 increase, placental insufficiency leads to increase, Preeclampsia
1743 Decrease, Cuticular chitin content leads to Increase, Premature molting
2171 Decrease, Digestion of old cuticle leads to Increase, Premature molting
773 Increase, cell proliferation (hepatocytes) leads to Increase, Preneoplastic foci (hepatocytes)
789 Increase, Regenerative cell proliferation (hepatocytes) leads to Increase, Preneoplastic foci (hepatocytes)
2834 Tissue resident cell activation leads to Increase, Pro-Inflammatory Mediators
2338 Increase, DNA Damage leads to Increase, Programmed cell death
2347 Decrease, MMP leads to Increase, Programmed cell death
1832 Activation, Tissue resident cells (Kuppfer cells) leads to Increase, proinflammatory mediators (TNFalpha)
939 Activation, Epidermal Growth Factor Receptor leads to Increased goblet cell proliferation
970 Activation, EGFR leads to Increased goblet cell proliferation
2089 Increase, ROS production leads to Increase, Protein oxidation
2801 Hemocyanin Bohr effect decrease leads to behavioral change leading to possible reduced feeding opportunity
279 Damaging, Red blood cells; hemolysis leads to Increase, RBC congestion in liver
1740 Decrease, PSII activity leads to Increase, ROS
1875 Increase, Mitochondrial complex III antagonism leads to Increase, ROS
2227 N/A, Mitochondrial dysfunction 1 leads to Increase, ROS
2887 Up Regulation, CYP1A1 leads to Increase, ROS
189 Disruption, Mitochondrial electron transport chain leads to Increase, ROS production
911 Disruption, Lysosome leads to Increase, ROS production
1631 Cell damage sensing leads to Increase, ROS production
2186 Increase, Complex III dysfunction leads to Increase, ROS production
2189 Increase, Complex I dysfunction leads to Increase, ROS production
2220 Increase, Oxygen consumption leads to Increase, ROS production
2224 N/A, Mitochondrial dysfunction 1 leads to Increase, ROS production
2304 Binding of agonist, Angiotensin II receptor type 1 receptor (AT1R) leads to Increase, ROS production
2557 Energy Deposition leads to Increase, ROS production
2893 Induction, CYP1A2/CYP1A5 leads to Increase, ROS production
778 Increase, Inflammation (corneal cells) leads to Increase, Regenerative cell proliferation (corneal cells)
781 Increase, Inflammation leads to Increase, Regenerative cell proliferation (forestomach epithelial cells)
788 Increase, Cytotoxicity (hepatocytes) leads to Increase, Regenerative cell proliferation (hepatocytes)
726 Increase, Necrosis (terminal bronchiolar cells) leads to Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells)
708 Increase, Cytotoxicity (renal tubular cell) leads to Increase, Regenerative cell proliferation (tubular epithelial cells)
784 Increase, Cytotoxicity (tubular epithelial cells) leads to Increase, Regenerative cell proliferation (tubular epithelial cells)
796 Increase, Cytotoxicity (urothelial cells) leads to Increase, Regenerative cell proliferation (urothelial cells)
2084 cell injury leads to Increase, Regenerative cell proliferation (urothelial cells)
254 Increase, Plasma vitellogenin concentrations leads to Increase, Renal pathology due to VTG deposition
888 Increase, Tissue Degeneration, Necrosis & Atrophy leads to Increase, Respiratory or Squamous Metaplasia
1459 Increased, hippocampal hyperdepolarization leads to Increase, seizure
2740 Delay, Ovarian maturation leads to Increase, sex ratio (F/M)
891 Increased, Induced Mutations in Critical Genes leads to Increase, Site of Contact Nasal Tumors
894 Increase, Mutations in Critical Genes leads to Increase, Site of Contact Nasal Tumors
895 Increase, Cell Proliferation leads to Increase, Site of Contact Nasal Tumors
2683 dimerization, AHR/ARNT leads to Increase, slincR expression
2687 Activation, AhR leads to Increase, slincR expression
2062 Increased inflammatory immune responses leads to Increase, the risk of acute respiratory failure
2762 Hyperinflammation leads to Increase, the risk of acute respiratory failure
769 Decrease, Serum thyroid hormone (T4/T3) leads to Increase, Thyroid-stimulating hormone (TSH)
2420 T4 in serum, Decreased leads to Increase, Thyroid-stimulating hormone (TSH)
2425 Increased, Thyroid-stimulating hormone (TSH) leads to Increase, Thyroid-stimulating hormone (TSH)
887 Increase, Cytotoxicity leads to Increase, Tissue Degeneration, Necrosis & Atrophy
2177 Increase, Necrosis leads to Increase, Tissue/organ damage
2181 Increase, Abnormal osmoregulation leads to Increase, Tissue/organ damage
2185 Increase, Apoptosis leads to Increase, Tissue/organ damage
2191 Apoptosis leads to Increase, Tissue/organ damage
1443 Increase, myosin light chain phosphorylation leads to Increase, vascular smooth muscle contraction
2737 Increased, Estrogen receptor (ER) activity leads to Increase, Vitellogenin mRNA
128 Agonism, Estrogen receptor leads to Increase, Vitellogenin synthesis in liver
2067 Increase plasma Ang II leads to Increase,collagen synthesis
2508 Heart failure leads to Upregulation of ACE2
1079 Activation, beta-2 adrenergic receptor leads to Increased activity, beta-2 adrenergic receptor
2881 ERa inactivation leads to Increased adipocyte numbers
2880 ERa inactivation leads to Increased adipocyte size
1609 Activation of specific nuclear receptors, PPAR-gamma activation leads to increased adipogenesis
1611 activation of CEBPA leads to increased adipogenesis
2322 Induced, Angiotensin (Ang) II accumulation leads to Increased Ang II type 1 receptor (AT1R)
2327 Increased AngII leads to Increased Ang II type 1 receptor (AT1R)
2435 Increase plasma Ang II leads to Increased Ang II type 1 receptor (AT1R)
2065 ACE2 enzymatic inhibition leads to Increased AngII
2137 Downregulation of ACE2 leads to Increased AngII
2297 Binding to ACE2 leads to Increased AngII
2326 Hyperactivation of ACE/Ang-II/AT1R axis leads to Increased AngII
1068 Increased, Hyperplasia (follicular cells) leads to Increased Apoptosis, Adenomas/carcinomas (follicular cell)
1645 GR Agonist, Activation leads to Increased apoptosis, decreased Leydig Cells
2029 Increased monitor peptide leads to Increased blood CCK level
1954 plasma homocysteine increases leads to brain Homocysteine level increases
1578 Excitation, Trigeminal nerve excitation leads to Increased CGRP
451 AchE Inhibition leads to Increased Cholinergic Signaling
456 ACh Synaptic Accumulation leads to Increased Cholinergic Signaling
2030 Increased blood CCK level leads to Increased acinar cell exocrine secretion
1949 CBS inhibition leads to Homocysteine increases
1950 MTHFR inhibition leads to Homocysteine increases
1951 Methionine synthase leads to Homocysteine increases
1952 betaine-homocysteine methyltransferase inhibition leads to Homocysteine increases
2061 Increased proinflammatory mediators leads to Increased inflammatory immune responses
2512 dysfunction of microcirculation leads to Increased inflammatory immune responses
2028 Inhibition, trypsin leads to Increased monitor peptide
1319 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to increased mantel display
1336 Increased, serotonin (5-HT) leads to increased mantel display
2609 Increase, Mutations leads to Increase,miRNA levels
2729 Increase chromosomal aberrations leads to Increase,miRNA levels
2809 Energy Deposition leads to Modified Proteins
2812 Oxidative Stress leads to Modified Proteins
263 Induction, Pre-mature molting leads to Increased Mortality
432 Increased, Atrioventricular block and bradycardia leads to Increased Mortality
433 Respiratory distress/arrest leads to Increased Mortality
434 Increased Cholinergic Signaling leads to Increased Mortality
452 AchE Inhibition leads to Increased Mortality
607 Increased, Ataxia, paralysis, or hyperactivity leads to Increased Mortality
703 Increased, cardiac arrthymia leads to Increased Mortality
757 N/A, Ataxia, paralysis, or hyperactivity leads to Increased Mortality
1050 Induction, Somatic muscle paralysis leads to Increased Mortality
1056 Inhibition, Feeding leads to Increased Mortality
1136 Occurrence, cardiac arrthymia leads to Increased Mortality
1141 Occurrence, cardiac arrhythmia leads to Increased Mortality
1190 Increase, Incomplete ecdysis leads to Increased Mortality
1491 Decreased, Population trajectory leads to Increased Mortality
2012 Impaired coordination and movement leads to Increased Mortality
2135 Increase, the risk of acute respiratory failure leads to Increased Mortality
2212 Reduced, Swimming performance leads to Increased Mortality
2213 Reduced, Posterior swim bladder inflation leads to Increased Mortality
2231 Reduced, Hearing leads to Increased Mortality
2375 Altered, Visual function leads to Increased Mortality
2406 Decreased, Eye size leads to Increased Mortality
2466 Increased, Kidney Failure leads to Increased Mortality
2657 Sensory axonal peripheral neuropathy leads to Increased Mortality
2852 Torsades de Pointes leads to Increased Mortality
2855 Increased,Cardiac dysfunction leads to Increased Mortality
2429 TLR9 activation leads to MyD88 activation
1583 Excitation, Trigeminal nerve excitation leads to Increased NKA
1192 Increased, serotonin (5-HT) 1 leads to increased or inappropriate, mantel display
1953 Homocysteine increases leads to plasma homocysteine increases
1763 Tissue resident cell activation leads to Increased pro-inflammatory mediators
1776 Cell injury/death leads to Increased pro-inflammatory mediators
2432 Increase activation, Nuclear factor kappa B (NF-kB) leads to Increased pro-inflammatory mediators
2772 Oxidative Stress leads to Increased pro-inflammatory mediators
1784 Increase, Mitochondrial complex III antagonism leads to Increased reactive oxygen species (in the mitochondria)
1785 Mitochondrial Complex IV inhibition leads to Increased reactive oxygen species (in the mitochondria)
1786 Mitochondrial Complex V inhibition leads to Increased reactive oxygen species (in the mitochondria)
1790 Mitochondrial Complex I inhibition leads to Increased reactive oxygen species (in the mitochondria)
1941 Mitochondrial Injury leads to Increased reactive oxygen species (in the mitochondria)
1958 N/A, Mitochondrial dysfunction 1 leads to Increased reactive oxygen species (in the mitochondria)
1278 Leukocyte infiltration leads to Respiratory irritability
1581 Increase, hypertension leads to Respiratory irritability
1587 Increased CGRP leads to Respiratory irritability
1771 Increased Airway Hyper-responsiveness,Cough, Dyspnea leads to Respiratory irritability
1772 SP (Substance P) release, Local increase of SP leads to Respiratory irritability
1773 Increased NKA leads to Respiratory irritability
2310 SARS-CoV-2 cell entry leads to SARS-CoV-2 production
2497 IFN-I response, antagonized leads to SARS-CoV-2 production
2328 Increased, Reactive oxygen species leads to Increased Sodium-sensitive hypertension
2697 Inhibition CerS leads to Increased S1-P
1591 HDL-SAA formation leads to Systemic cholesterol increased
2314 SARS-CoV-2 cell entry leads to Increased viral transcription and replication
1435 Decreased, extracellular serotonin leads to Increased, 5-HT3
706 Increased, Binding of chemicals to 2u (serum) leads to Increased, Accumulation of alpha2u microglobulin (proximal tubular epithelium)
67 Cell injury/death leads to Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells)
236 Peptide Oxidation leads to Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells)
1705 Loss of alveolar capillary membrane integrity leads to Activation of Th2 cells
1120 Increased, lactotroph hyperplasia and hypertrophy leads to Increased, adenomas (pituitary)
1116 Hyperplasia, Mammary gland leads to Increased, Adenomas/carcinomas (mammary)
1117 Increased, latency period leads to Increased, Adenomas/carcinomas (mammary)
1124 Increased, hyperplasia (mammary gland) leads to Increased, Adenomas/carcinomas (mammary)
1107 Increased, Hyperplasia (glandular epithelial cells of endometrium) leads to Increased, adenosquamous carcinomas of endometrium
1071 Activation of specific nuclear receptors, PPAR-gamma activation leads to Increased, adipogenesis
1448 Decreased, neuroplasticity leads to Increased, agitation
593 N/A, hypoxia leads to Increased, amputations
1266 Increased, Proliferation (Endothelial cells) leads to Increased, Angiogenesis
1267 Increased, Migration (Endothelial Cells) leads to Increased, Angiogenesis
567 Increase, Energetic demands and therefore metabolic stress leads to Increased, Appetite and hunger
606 Overactivation, muscle contraction leads to Increased, Ataxia, paralysis, or hyperactivity
449 AchE Inhibition leads to Increased, Atrioventricular block and bradycardia
454 ACh Synaptic Accumulation leads to Increased, Atrioventricular block and bradycardia
590 Inhibition, sodium channel leads to Increased, Atrioventricular block and bradycardia
594 Decreased, Sodium conductance 1 leads to Increased, Atrioventricular block and bradycardia
2869 Increased, glutamate leads to increased, Bax expression
1134 Occurrence, renal proximal tubular necrosis leads to Increased, blood potassium concentration
1131 Inhibition, organic anion transporter 1 (OAT1) leads to Increased, blood uric acid concentration
1156 Occurrence, renal proximal tubular necrosis leads to Increased, blood uric acid concentration
702 Altered, Action Potential leads to Increased, cardiac arrthymia
884 Not Increased, Circulating Ketone Bodies leads to Increased, Catabolism of Muscle Protein
1129 Increased, secretion of local growth factors leads to Increased, Cell Proliferation (mesothelium)
1098 prolonged, elevation of serun CCK leads to Increased, Cellular proliferation / hyperplasia of acinar cells
752 Activation, Glutamate-gated chloride channel leads to Increased, Chloride conductance
1051 Activation, ionotropic GABA Receptor chloride channel leads to Increased, Chloride conductance
1057 Activation, Glutamate-gated chloride channels leads to Increased, Chloride conductance
1096 Increased, PPAR-alpha activation leads to Increased, cholestasis
1101 Decreased, bile flow leads to Increased, cholestasis
699 Upregulated, Spindle assembly checkpoint protein Mad2-oocyte leads to Increased, Chromosome misseggregation
1208 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to Increased, cilia movement
1209 Increased, serotonin (5-HT) leads to Increased, cilia movement
1111 prolonged, estrus leads to Increased, circulating estrogen levels
1118 interruption, Ovulation leads to Increased, circulating estrogen levels
2583 Increased, estrogens leads to Increased, circulating estrogen levels
2269 Binding, Transthyretin in serum leads to Increased, Clearance of thyroxine from serum
2272 Increased, Free serum thyroxine (T4) leads to Increased, Clearance of thyroxine from serum
2478 Induction, Upregulation of glucuronyltransferase activity leads to Increased, Clearance of thyroxine from serum
2479 Increased, Hepatic thyroid hormone uptake/transport leads to Increased, Clearance of thyroxine from serum
2885 Increase, Glucuronidation of T4 leads to Increased, Clearance of thyroxine from serum
351 Increased, Induced Mutations in Critical Genes leads to Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci
352 Formation, Pro-mutagenic DNA Adducts leads to Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci
694 Reduced, Maturation inducing steroid receptor signalling, oocyte leads to Increased, cyclic adenosine monophosphate
482 Activation, SREBF1 leads to Increased, De Novo FA synthesis
483 Activation, ChREBP leads to Increased, De Novo FA synthesis
492 Up Regulation, FAS leads to Increased, De Novo FA synthesis
517 Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1) leads to Increased, De Novo FA synthesis
1606 Activation, LXR alpha leads to Increased, De Novo FA synthesis
1449 Decreased, neuroplasticity leads to Increased, depression
1025 Abnormal, Morphogenesis leads to Increased, Developmental Defects
1036 Insufficiency, Vascular leads to Increased, Developmental Defects
2145 Reduction, E2 Synthesis by the undifferentiated gonad leads to Increased, Differentiation to Testis
2167 Inhibition, Aromatase leads to Increased, Differentiation to Testis
2260 Agonism, Androgen receptor leads to Increased, Differentiation to Testis
389 Decreased, Lymphocytes leads to Increased, Disease susceptibility
1965 Increased, Reactive oxygen species leads to Increased, DNA damage and mutation
2661 Secondary genotoxicity leads to Increased, DNA damage and mutation
2663 Interaction with the lung cell membrane leads to Increased, DNA damage and mutation
1362 Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK leads to Increased, DNA Damage-Repair
1247 Increase, Cell Proliferation (Epithelial Cells) leads to Increased, Ductal Hyperplasia
1248 Decreased, Apoptosis (Epithelial Cells) leads to Increased, Ductal Hyperplasia
2867 decreased, IQ leads to increased, Economic Burden
1460 Increase, seizure leads to Increased, epilepsy
1550 Increased, seizure leads to Increased, epilepsy
1246 Activation, Estrogen receptor leads to Increased, ER binding to DNA (classical pathway)
1249 Activation, Estrogen receptor leads to Increased, ER binding to T.F. to DNA (non-classical pathway)
1295 Increased, Non-genomic signaling leads to Increased, ER binding to T.F. to DNA (non-classical pathway)
733 Decreased, Prolactin leads to Increased, Estrogen receptor (ER) activity
2736 Increase, Alcohol dehydrogenase leads to Increased, Estrogen receptor (ER) activity
2582 Increased, Steroidogenic acute regulatory protein (StAR) leads to Increased, estrogens
1707 Increased cellular proliferation and differentiation leads to Increased extracellular matrix deposition
2324 Increased, Reactive oxygen species leads to Increased extracellular matrix deposition
2891 Leukocyte recruitment/activation leads to Increased extracellular matrix deposition
2892 Activation, Stellate cells leads to Increased extracellular matrix deposition
1430 Decreased, serotonin transporter activity leads to Increased, extracellular serotonin
1527 Increased, synaptic release leads to Increased, extracellular serotonin
496 Activation, AhR leads to Increased, FA Influx
501 Up Regulation, CD36 leads to Increased, FA Influx
1659 demethylation, PPARg promoter leads to Increased, FA Influx
2262 Up Regulation, CD36 leads to Increased, Fatty acid uptake
1706 Activation of Th2 cells leads to Increased cellular proliferation and differentiation
1076 Increased, proliferation of mesenchymal cells leads to Increased, Firbrosarcoma
639 Increase, cilia movement leads to Increased, foot detachment
642 Increased, muscular waves in foot leads to Increased, foot detachment
1175 Increased, water retention in foot leads to Increased, foot detachment
2246 Displacement, Serum thyroxine (T4) from transthyretin leads to Increased, Free serum thyroxine (T4)
2249 Displacement, Serum thyroxine (T4) from carrier protein leads to Increased, Free serum thyroxine (T4)
2271 Binding, Transthyretin in serum leads to Increased, Free serum thyroxine (T4)
1452 Activated, presynaptic neuron 1 leads to Increased, glutamate
1858 Activation, Muscarinic Acetylcholine Receptors leads to Increased, glutamate
1861 Occurrence, Epileptic seizure leads to Increased, glutamate
1890 Occurrence, Focal Seizure leads to Increased, glutamate
2782 Status epilepticus leads to Increased, glutamate
1078 Increased, proliferation of mesenchymal cells leads to Increased, hemagiosarcoma
1204 Activation, Hepatic nuclear receptor(s) leads to Increased, Hepatic thyroid hormone uptake/transport
2247 Increased, Free serum thyroxine (T4) leads to Increased, Hepatic thyroid hormone uptake/transport
802 modulation, Unknown leads to Increased, HIF-1 alpha transcription
799 Inhibition, Prolyl hydroxylases leads to Increased, HIF-1 heterodimer
803 Increased, HIF-1 alpha transcription leads to Increased, HIF-1 heterodimer
1458 Activated, membrane depolarization leads to Increased, hippocampal hyperdepolarization
1067 Increased, Hypertrophy and proliferation (follicular cell) leads to Increased, Hyperplasia (follicular cells)
1106 squamous metaplasia, aberrant basal cells leads to Increased, Hyperplasia (glandular epithelial cells of endometrium)
1122 Increased, prolactin secretion leads to Increased, hyperplasia (mammary gland)
1066 Increased, Thyroid-stimulating hormone (TSH) leads to Increased, Hypertrophy and proliferation (follicular cell)
1075 Increased, secretion of local growth factors leads to Increased, IGF-1 (mouse)
547 Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts leads to Increased, Induced Mutations in Critical Genes
890 Increase, Cell Proliferation leads to Increased, Induced Mutations in Critical Genes
716 Inhibition, Pyruvate dehydrogenase kinase (PDK) enzyme leads to Increased, Induction of pyruvate dehydrogenase (PDH)
1125 persistent, cytotoxicity (pleura or peritoneum) leads to Increased, inflammation
1047 Increased, Chloride influx leads to Increased, Inhibitory postsynaptic potential
1053 Increased, Neuronal synaptic inhibition leads to Increased, Inhibitory postsynaptic potential
548 Formation, Pro-mutagenic DNA Adducts leads to Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts
361 Overactivation, NMDARs leads to Increased, Intracellular Calcium overload
2701 Activation, mGLUr leads to Increased, Intracellular Calcium overload
2702 Activation, IP3R leads to Increased, Intracellular Calcium overload
2708 Increase, Cell membrane depolarization leads to Increased, Intracellular Calcium overload
2783 Status epilepticus leads to Increased, Intracellular Calcium overload
1427 Decreased, serotonin transporter activity leads to Increased, intracellular chloride (Cl-)
1464 Activate, GABA-A receptor leads to Increased, intracellular chloride (Cl-)
1524 Increased, serotonin transporter activity leads to Increased, intracellular serotonin
1426 Decreased, serotonin transporter activity leads to Increased, intracellular sodium (Na+)
1454 Activated, NMDA receptor leads to Increased, intracellular sodium (Na+)
1306 Increased, Motility leads to Increased, Invasion
2572 Activation, AhR leads to Increased, Invasion
2573 Increase, Inflammation leads to Increased, Invasion
751 N/A, Unknown leads to Increased, Kidney Failure
2461 Increase, Apoptosis leads to Increased, Kidney Failure
2465 Increase, Necrosis leads to Increased, Kidney Failure
2648 Occurrence, Kidney toxicity leads to Increased, Kidney Failure
2626 Agonism, Estrogen Receptor alpha leads to Increased, Kisspeptin signalling
2665 Activation, estrogen receptor alpha leads to Increased, Kisspeptin signalling
1119 Increased, circulating estrogen levels leads to Increased, lactotroph hyperplasia and hypertrophy
1115 Hyperplasia, Mammary gland leads to Increased, latency period
1123 Increased, hyperplasia (mammary gland) leads to Increased, latency period
507 Up Regulation, LDLR (low density lipoprotein receptor) leads to Increased, LDL uptake
196 Abnormal, Morphogenesis leads to Increased, Lethality
296 Increased, Structural malformations leads to Increased, Lethality
1544 Increased, leukocyte adherence leads to Increased, leukocyte activation
1543 Reduced, PTGS2 function leads to Increased, leukocyte adherence
793 Decrease, Bioactivation of testosterone leads to Increased, Leutinizing hormone (LH)
1404 Activation, SCD-1 leads to Increased, lipogenesis
1422 Activation, FAS leads to Increased, lipogenesis
1077 Increased, proliferation of mesenchymal cells leads to Increased, liposarcoma
486 Increased, Triglyceride formation leads to Increased, Liver Steatosis
515 Accumulation, Fatty acid leads to Increased, Liver Steatosis
538 Inhibition, Mitochondrial fatty acid beta-oxidation leads to Increased, Liver Steatosis
617 Decreased, Mitochondrial fatty acid beta-oxidation leads to Increased, Liver Steatosis
1607 Increased, De Novo FA synthesis leads to Increased, Liver Steatosis
1662 Activation, SREBF1 leads to Increased, Liver Steatosis
1694 Increase, cytosolic fatty acid leads to Increased, Liver Steatosis
2040 Decreased, Mitochondrial Fatty Acid Beta Oxidation leads to Increased, Liver Steatosis
2042 Decreased, PPAR-alpha activation leads to Increased, Liver Steatosis
2263 Increased, Fatty acid uptake leads to Increased, Liver Steatosis
2265 Accumulation, Triglyceride leads to Increased, Liver Steatosis
637 Increase, cilia movement leads to Increased, locomotion
641 Increased, muscular waves in foot leads to Increased, locomotion
1189 Increased, serotonin (5-HT) 1 leads to Increased, locomotion
744 Decreased, Testosterone binding to androgen receptor (hypothalamus) leads to Increased, Luteinizing hormone (LH)
2146 Increased, Differentiation to Testis leads to Increased, Male Biased Sex Ratio
2349 Agonism, Androgen receptor leads to Increased, Male Biased Sex Ratio
2350 Inhibition, Aromatase leads to Increased, Male Biased Sex Ratio
1263 Induction, Male reproductive tract leads to Increased, Male offspring
1207 Increased, serotonin (5-HT) leads to Increased, mantel display
1130 Increased, Cell Proliferation (mesothelium) leads to Increased, mesotheliomas
2419 Increase, Cell Proliferation leads to Increased, mesotheliomas
2571 Activation, AhR leads to Increased, Migration (Endothelial Cells)
1305 Altered, Protein Production leads to Increased, Motility
2570 Activation, AhR leads to Increased, Motility
640 Increased, serotonin (5-HT) 1 leads to Increased, muscular waves in foot
1316 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to Increased, muscular waves in foot
1332 Increased, serotonin (5-HT) leads to Increased, muscular waves in foot
1052 Increased, Chloride conductance leads to Increased, Neuronal synaptic inhibition
1294 Activation, Estrogen receptor leads to Increased, Non-genomic signaling
1308 Increased, Second Messenger Production leads to Increased, Non-genomic signaling
1696 Increased, Reactive oxygen species leads to increased, oncotic necrosis
2632 Impaired, Oocyte maturation and ovulation leads to Increased, Oocyte Atresia
1212 Increased, serotonin (5-HT) leads to Increased, oocyte maturation
1337 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to Increased, oocyte maturation
283 Increase, ROS production leads to Increased, Oxidative damage
1126 persistent, cytotoxicity (pleura or peritoneum) leads to Increased, Oxidative Stress
1158 Increased, blood uric acid concentration leads to Increased, Oxidative Stress
1159 Occurrence, renal ischemia leads to Increased, Oxidative Stress
1162 Increased, Reactive oxygen species leads to Increased, Oxidative Stress
1299 Altered, Protein Production leads to Increased, Oxidative Stress
2390 Ionizing Energy leads to Increased, Oxidative Stress
2617 Increase in RONS leads to Increased, Oxidative Stress
2642 Altered expression of NRF2 pathway-dependent genes leads to Increased, Oxidative Stress
1525 Increased, intracellular serotonin leads to Increased, packaged serotonin
1099 Increased, Cellular proliferation / hyperplasia of acinar cells leads to Increased, Pancreatic acinar tumors
1959 Homocysteine increases leads to Plasma HCY level
775 Inhibition, 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) enzyme leads to Increased, Plasma tyrosine
1211 premature, Spawning leads to Increased, Population
1215 Increased, Reproductive Success leads to Increased, Population
588 Reduced, swimming speed leads to Increased, predation
589 Reduced, feeding 1 leads to Increased, predation
646 Decreased, sheltering leads to Increased, predation
651 Decreased, locomotion leads to Increased, predation
1112 prolonged, estrus leads to Increased, prolactin exposure
1121 Decreased, Dopaminergic activity leads to Increased, prolactin secretion
1303 Altered, Protein Production leads to Increased, Proliferation (Endothelial cells)
1074 Increased, secretion of local growth factors leads to Increased, proliferation of mesenchymal cells
342 Increased, Induced Mutations in Critical Genes leads to Increased, Proliferation/Clonal Expansion of Mutant Cells (Pre-Neoplastic Lesions/Altered H
344 Formation, Pro-mutagenic DNA Adducts leads to Increased, Proliferation/Clonal Expansion of Mutant Cells (Pre-Neoplastic Lesions/Altered H
1161 Unknown, MIE leads to Increased, Reactive oxygen species
1695 Increased, Liver Steatosis leads to Increased, Reactive oxygen species
1964 Recruitment of inflammatory cells leads to Increased, Reactive oxygen species
2319 Binding of agonist, Angiotensin II receptor type 1 receptor (AT1R) leads to Increased, Reactive oxygen species
2323 Increased Ang II type 1 receptor (AT1R) leads to Increased, Reactive oxygen species
2379 Ionizing Energy leads to Increased, Reactive oxygen species
2416 Frustrated phagocytosis leads to Increased, Reactive oxygen species
2459 Oxidation, Glutathione leads to Increased, Reactive oxygen species
2548 Energy Deposition leads to Increased, Reactive oxygen species
2659 Increase, Cytotoxicity (epithelial cells) leads to Increased, Reactive oxygen species
2662 Interaction with the lung cell membrane leads to Increased, Reactive oxygen species
2878 Depletion, GSH leads to Increased, Reactive oxygen species
2901 ERa inactivation leads to Increased, Reactive oxygen species
1703 Increased proinflammatory mediators leads to Recruitment of inflammatory cells
1963 Release, Cytokine leads to Recruitment of inflammatory cells
2490 Disruption of the intestinal barrier leads to Recruitment of inflammatory cells
2493 ACE2 dysregulation leads to Recruitment of inflammatory cells
2544 Gut dysbiosis leads to Recruitment of inflammatory cells
2876 Increased fat mass leads to Recruitment of inflammatory cells
1213 Increased, oocyte maturation leads to Increased, Reproductive Success
1214 Increased, mantel display leads to Increased, Reproductive Success
1325 induced spawning leads to Increased, Reproductive Success
1326 Induced parturition leads to Increased, Reproductive Success
1307 Activation, Estrogen receptor leads to Increased, Second Messenger Production
1088 Increased, secretion of GnRH from hypothalamus leads to Increased, secrection of FSH from anterior pituitary
1084 Decreased, Ovarian E2 leads to Increased, secretion of GnRH from hypothalamus
1087 Decrease, E2 blood concentrations at hypothalamus leads to Increased, secretion of GnRH from hypothalamus
2580 Suppression, Estrogen receptor (ER) activity leads to Increased, secretion of GnRH from hypothalamus
1089 Increased, secretion of GnRH from hypothalamus leads to Increased, secretion of LH from anterior pituitary
1072 Activation of specific nuclear receptors, PPAR-gamma activation leads to Increased, secretion of local growth factors
1073 Increased, adipogenesis leads to Increased, secretion of local growth factors
1127 Increased, inflammation leads to Increased, secretion of local growth factors
1128 Increased, Oxidative Stress leads to Increased, secretion of local growth factors
1622 Sustained inflammatory cytokine release leads to Increased, secretion of local growth factors
1623 Increase, ROS production leads to Increased, secretion of local growth factors
1632 Cell damage sensing leads to Increased, secretion of local growth factors
1702 Interaction with the lung cell membrane leads to Increased proinflammatory mediators
2052 SARS-CoV-2 cell entry leads to Increased proinflammatory mediators
2300 Increased AngII leads to Increased proinflammatory mediators
2303 TLR Activation/Dysregulation leads to Increased proinflammatory mediators
2306 Inhibition, Nuclear factor kappa B (NF-kB) leads to Increased proinflammatory mediators
2309 Increase activation, Nuclear factor kappa B (NF-kB) leads to Increased proinflammatory mediators
2315 Increased viral transcription and replication leads to Increased proinflammatory mediators
2353 Bradykinin, activated leads to Increased proinflammatory mediators
2356 Hypofibrinolysis leads to Increased proinflammatory mediators
2415 Frustrated phagocytosis leads to Increased proinflammatory mediators
2649 Covalent Binding, Protein leads to Increased proinflammatory mediators
2760 Increase, Cell death leads to Increased proinflammatory mediators
2761 Recruitment of inflammatory cells leads to Increased proinflammatory mediators
1445 Increased, 5-HT3 leads to Increased, seizure
1530 Decreased, 5-HT3 leads to Increased, seizure
1549 Increased, hippocampal hyperdepolarization leads to Increased, seizure
643 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to Increased, serotonin (5-HT)
635 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to Increased, serotonin (5-HT) 1
810 TH synthesis, Decreased leads to Increased, Serum creatinine
1562 Reduced, fatty acid beta oxidation leads to Increased, steatosis
2581 Increased, secretion of LH from anterior pituitary leads to Increased, Steroidogenic acute regulatory protein (StAR)
197 Abnormal, Morphogenesis leads to Increased, Structural malformations
1526 Increased, packaged serotonin leads to Increased, synaptic release
1063 Increased, induction of UDPGT's in liver leads to Increased, T4/T3 catabolism
2428 Induction, Upregulation of glucuronyltransferase activity leads to Increased, T4/T3 catabolism
1065 Decreased, serum T4/T3 leads to Increased, Thyroid-stimulating hormone (TSH)
2238 Decreased, Triiodothyronine (T3) in tissues leads to Increased, Thyroid-stimulating hormone (TSH)
2422 T4 in serum, Decreased leads to Increased, Thyroid-stimulating hormone (TSH)
2240 Increased, Thyroid-stimulating hormone (TSH) leads to Increased, Thyroxine (T4) in serum
484 Increased, De Novo FA synthesis leads to Increased, Triglyceride formation
493 Up Regulation, SCD-1 leads to Increased, Triglyceride formation
514 Accumulation, Fatty acid leads to Increased, Triglyceride formation
1658 Increased, FA Influx leads to Increased, Triglyceride formation
1200 Inhibition, Deiodinase 3 leads to Increased, Triiodothyronine (T3) in tissues
2577 Apoptosis leads to tumor growth
2268 Increased, Free serum thyroxine (T4) leads to Increased, Uptake of thyroxine into tissue
1172 Increased, serotonin (5-HT) 1 leads to Increased, valve movement
1223 Increased, water retention in foot leads to Increased, valve movement
1317 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to Increased, valve movement
1327 Increased, serotonin (5-HT) leads to Increased, valve movement
570 Suppression, Immune system leads to Increased, Viral susceptibility
1216 Increased, valve movement leads to Increased, water pumping
1217 Increase, cilia movement leads to Increased, water pumping
1174 Increased, valve movement leads to Increased, water retention in foot
1224 Increased, water pumping leads to Increased, water retention in foot
2854 Occurrence, cardiac arrhythmia leads to Increased,Cardiac dysfunction
1630 Cell damage sensing leads to Sustained inflammatory cytokine release
1955 brain Homocysteine level increases leads to Neuronal dysfunctions induction
2299 Binding to ACE2 leads to ACE2 enzymatic inhibition
1322 increased mantel display leads to Induced parturition
1334 Increased, valve movement leads to Induced parturition
1335 Increase, cilia movement leads to Induced parturition
1320 Increased, valve movement leads to induced spawning
1321 Increase, cilia movement leads to induced spawning
1328 Increased, oocyte maturation leads to induced spawning
1329 Increased, cilia movement leads to induced spawning
2294 Binding to ACE2 leads to Induced, Angiotensin (Ang) II accumulation
2321 ACE2 enzymatic inhibition leads to Induced, Angiotensin (Ang) II accumulation
2519 Degradation of Ang-II reduced leads to Induced, Angiotensin (Ang) II accumulation
1960 Plasma HCY level leads to dysfunction of microcirculation
2511 Endothelial cell dysfunction leads to dysfunction of microcirculation
1220 increased or inappropriate, mantel display leads to induced, parturition
1226 Increased, water pumping leads to induced, parturition
2068 Increase,collagen synthesis leads to Induction lung fibrosis
2020 Binding to estrogen receptor (ER)-α leads to Induction of GATA3 expression
2536 hERG channel biogenesis interference leads to Induction of hERG trafficking defects
116 Increase, EcR agonism leads to Induction, Chitin degradation and resorption
869 Activation, AhR leads to Induction, CYP1A2/CYP1A5
1261 Activation, Juvenile hormone receptor leads to Induction, Doublesex1 gene
1625 Increased, secretion of local growth factors leads to EMT
1653 TGFbeta pathway activation leads to EMT
1723 Activation of TGF-β signaling leads to EMT
1724 Increase, Inflammation leads to EMT
2153 Activation, TGF-beta pathway leads to EMT
2613 Antagonism, Estrogen receptor leads to EMT
385 Activation, Glucocorticoid Receptor leads to Induction, IKB inhibitory protein
93 Production, Critical Metabolites (CGA 330050 and CGA 265307) leads to Induction, Liver “Dysfunctional” Changes by CGA 330050
1262 Induction, Doublesex1 gene leads to Induction, Male reproductive tract
851 Occurrence, Cytoplasmic vacuolization (hepatocyte) leads to Induction, Microvesicular fat
853 Occurrence, Ballooning degeneration (hepatocyte) leads to Induction, Microvesicular fat
855 Occurrence, Cytoplasmic vacuolization (Bile duct cell) leads to Induction, Microvesicular fat
857 Occurrence, Cytoplasmic vacuolization (kupffer cell) leads to Induction, Microvesicular fat
1514 Hepatocytotoxicity leads to Sustained proliferation
1058 Increased, Inhibitory postsynaptic potential leads to Induction, pharyngeal muscle paralysis
70 Induction, Chitin degradation and resorption leads to Induction, Pre-mature molting
1049 Inhibition, Motor neuron activity leads to Induction, Somatic muscle paralysis
1054 Increased, Inhibitory postsynaptic potential leads to Induction, Somatic muscle paralysis
299 Induction, Sustained Hepatotoxicity leads to Induction, Sustained Cell Proliferation
159 Inhibition, Inducible Nitric Oxide Synthase by Metabolite CGA 265307 leads to Induction, Sustained Hepatotoxicity
1205 Activation, Hepatic nuclear receptor(s) leads to Induction, Upregulation of glucuronyltransferase activity
2482 Activation, Pregnane-X receptor, NR1l2 leads to Induction, Upregulation of glucuronyltransferase activity
2883 Activation, AhR leads to Induction, Upregulation of glucuronyltransferase activity
1331 MLL translocation leads to IFL
994 Release, Cytokine leads to Infiltration, Inflammatory cells
925 Release, Cytokine leads to Infiltration, Inflammatory cytokines
1850 Oxidation of membrane lipids leads to Inflammatory events
1851 Oxidation/denatuation of membrane proteins leads to Inflammatory events
1852 Oxidation of DNA leads to Inflammatory events
1853 DNA photo-adducts leads to Inflammatory events
1854 Protein photo-adducts leads to Inflammatory events
916 Infiltration, Inflammatory cells leads to Inflammation, Liver
926 Infiltration, Inflammatory cytokines leads to Inflammation, Liver
1473 Increase, angiogenesis leads to Inhibit, gastric ulcer formation
1474 Increase, platelet aggregation leads to Inhibit, gastric ulcer formation
1475 Activate, mucosal defense leads to Inhibit, gastric ulcer formation
1456 Treat, carbamazepine leads to Inhibit, voltage-gated sodium channel
2537 Direct hERG channel blockage leads to Inhibition of Ikr
2538 Induction of hERG trafficking defects leads to Inhibition of Ikr
1968 Substance - LS interaction leads to Inhibition of LS function.
2368 Loss of alveolar capillary membrane integrity leads to Inhibition of LS function.
1636 Thiol protein adducts leads to Inhibition of lysyl oxidase
1568 Release of G Proteins leads to Inhibition of Ca Channels
1569 Inhibition of Ca Channels leads to Inhibition of neurotransmitter release
2402 Inhibition of Fyna leads to Inhibition of Plxna2
2850 hERG channel blockade leads to Inhibition of rapid delayed rectifying potassium current
2078 Increase, Cripto-1 expression leads to Inhibition, Activin signaling
1062 Formation, The binding of FK506 with FKBP12 leads to Inhibition, Calcineurin Activity
1253 Binding, Immunophilins leads to Inhibition, Calcineurin Activity
1055 Induction, Somatic muscle paralysis leads to Inhibition, Feeding
1059 Induction, pharyngeal muscle paralysis leads to Inhibition, Feeding
2079 Inhibition, Activin signaling leads to Inhibition, Fin regeneration
2082 Increase, Cripto-1 expression leads to Inhibition, Fin regeneration
518 Activation, PXR/SXR leads to Inhibition, FoxA2
170 Induction, Liver “Dysfunctional” Changes by CGA 330050 leads to Inhibition, Inducible Nitric Oxide Synthase by Metabolite CGA 265307
1414 Activation, SHP leads to Inhibition, LRH-1
1412 Activation, SHP leads to Inhibition, LXR
473 Activation, AhR leads to Inhibition, Mitochondrial fatty acid beta-oxidation
511 Inhibition, PPAR alpha leads to Inhibition, Mitochondrial fatty acid beta-oxidation
537 Decreased, DHB4/HSD17B4 leads to Inhibition, Mitochondrial fatty acid beta-oxidation
1411 Activation, HSD17B4 leads to Inhibition, Mitochondrial fatty acid beta-oxidation
1048 Increased, Inhibitory postsynaptic potential leads to Inhibition, Motor neuron activity
933 Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I) leads to Inhibition, NADH-ubiquinone oxidoreductase (complex I)
229 Binding of antagonist, NMDA receptors leads to Inhibition, NMDARs
386 Induction, IKB inhibitory protein leads to Inhibition, Nuclear factor kappa B (NF-kB)
1827 Inhibition, IKK complex leads to Inhibition, Nuclear factor kappa B (NF-kB)
1870 Suppressed MyD88 leads to Inhibition, Nuclear factor kappa B (NF-kB)
1920 Impaired IL-1 signaling leads to Inhibition, Nuclear factor kappa B (NF-kB)
2001 Suppression of T cell activation leads to Inhibition, Nuclear factor kappa B (NF-kB)
2002 Impaired IL-1R1 signaling leads to Inhibition, Nuclear factor kappa B (NF-kB)
2305 Increase, ROS production leads to Inhibition, Nuclear factor kappa B (NF-kB)
2639 Increase, Mt Dysfunction leads to Inhibition, Nuclear factor kappa B (NF-kB)
510 Activation, LXR leads to Inhibition, PPAR alpha
1413 Inhibition, LXR leads to Inhibition, PPAR alpha
896 Activation, SHP leads to Inhibition, SREBP1c
1416 Increase, Fatty acid β-oxidation leads to Inhibition, Steatosis
865 Oxidation, Uroporphyrinogen leads to Inhibition, UROD
331 Binding, VEGF-A leads to Inhibition, VegfR2
334 Decreased, VegfR2 leads to Inhibition, VegfR2
1381 Activation, FOXO leads to Inhibition, Wnt pathway
838 Inhibition, Phospholipase A leads to Injury, Mitochondria
2703 Activation, mGLUr leads to Activation, IP3R
125 Impairment, Endothelial network leads to Insufficiency, Vascular
2907 Impaired insulin signaling leads to Insulin resistance
2865 T4 in serum, Decreased leads to Insulin resistance, increased
1016 Activation, Suppression of NFAT activation and hindrance of nuclear localization leads to Interference, nuclear localization of NFAT
1255 Suppression, IL-2 and IL-4 production leads to Interference, nuclear localization of NFAT
1508 Inhibition, Calcineurin Activity leads to Interference, nuclear localization of NFAT
2496 SARS-CoV-2 cell entry leads to IFN-I response, antagonized
1109 Decreased, LH Surge from anterior pituitary leads to interruption, Ovulation
2489 Increase, Cell death leads to Disruption of the intestinal barrier
2491 Recruitment of inflammatory cells leads to Disruption of the intestinal barrier
2533 Gut dysbiosis leads to Disruption of the intestinal barrier
2546 SARS-CoV-2 production leads to Disruption of the intestinal barrier
392 Reduction, Plasma 17beta-estradiol concentrations leads to irregularities, ovarian cycle
2525 Ovarian follicle pool, reduced leads to irregularities, ovarian cycle
1582 Excitation, Trigeminal nerve excitation leads to Irritation induced sneezing
954 Oxidation, Glutathione leads to S-Glutathionylation, eNOS
1698 Peptide Oxidation leads to S-Glutathionylation, eNOS
980 Peptide Oxidation leads to Decrease, GTPCH-1
952 Decrease, GTPCH-1 leads to Decrease, Tetrahydrobiopterin
953 Decrease, Tetrahydrobiopterin leads to Uncoupling, eNOS
955 S-Glutathionylation, eNOS leads to Uncoupling, eNOS
992 Peptide Oxidation leads to Decrease, AKT/eNOS activity
956 Uncoupling, eNOS leads to Depletion, Nitric Oxide
988 Decrease, AKT/eNOS activity leads to Depletion, Nitric Oxide
958 Depletion, Nitric Oxide leads to Impaired, Vasodilation
982 Impaired, Vasodilation leads to Increase, Vascular Resistance
2151 Pin-1 activation leads to TGFbeta expression
2157 AP-1 activation leads to TGFbeta expression
1777 Increased pro-inflammatory mediators leads to Leukocyte recruitment/activation
2890 Cell injury/death leads to Leukocyte recruitment/activation
1727 Oxidative Stress in Brain leads to Lipid Peroxidation
1516 Oxidative Stress leads to Liver Cancer
1517 Hepatocytotoxicity leads to Liver Cancer
1518 Sustained proliferation leads to Liver Cancer
1789 Necrotic Tissue leads to Liver Injury
1868 Activation, hepatic stellate cells leads to Liver Injury
1869 Apoptosis leads to Liver Injury
1494 CYP7B activity, inhibition leads to Locomotor activity, decreased
1495 7α-hydroxypregnenolone synthesis in the brain, decreased leads to Locomotor activity, decreased
1497 Dopamine release in the brain, decreased leads to Locomotor activity, decreased
1704 Recruitment of inflammatory cells leads to Loss of alveolar capillary membrane integrity
2173 Alveolar reopening leads to Loss of alveolar capillary membrane integrity
2255 Inhibition of LS function. leads to Loss of alveolar capillary membrane integrity
2284 Alveolar collapse leads to Loss of alveolar capillary membrane integrity
1971 Alveolar reopening leads to Loss of barrier function
2806 Overactivation, NMDARs leads to Loss of drebrin
2484 Hippocampal Physiology, Altered leads to Loss, Cochlear function
1967 Increase, Cell Proliferation leads to Lung cancer
1358 Production of α-smooth muscle actin leads to Lung fibrosis
1359 Collagen Deposition leads to Lung fibrosis
1725 EMT leads to Lung fibrosis
2139 Accumulation, Collagen leads to Lung fibrosis
1938 Impaired inguinoscrotal phase leads to Malformation, cryptorchidism
608 Reduction, testosterone level leads to Malformation, Male reproductive tract
807 Decreased, Testosterone leads to malformed, Male reproductive tract
2501 Neuronal network function, Decreased leads to Memory Loss
2908 Insulin resistance leads to Metabolic syndrome
2614 EMT leads to Metastasis, Breast Cancer
1945 Binding of inhibitor, mitochondrial complex IV leads to Mitochondrial Complex IV inhibition
1946 Binding of inhibitor, mitochondrial complex V leads to Mitochondrial Complex V inhibition
2192 Reactive Metabolite leads to Mitochondrial dysfunction
2827 Oxidative Stress leads to Mitochondrial dysfunction
2903 Increased, Oxidative Stress leads to Mitochondrial dysfunction
2904 Decreased, Mitochondrial fatty acid beta-oxidation leads to Mitochondrial dysfunction
1338 Decompartmentalization leads to Mitochondrial impairment
1339 Direct mitochondrial inhibition leads to Mitochondrial impairment
1340 narcosis leads to Mitochondrial impairment
1787 Decrease in mitochondrial oxidative phosphorylation leads to Mitochondrial Injury
1788 Increased reactive oxygen species (in the mitochondria) leads to Mitochondrial Injury
2714 Oxidative Stress leads to Mitochondrial Injury
2447 FOXJ1 Protein, Decreased leads to Motile Cilia Number/Length, Decreased
2442 CBF, Decreased leads to MCC, Decreased
2446 Mucus Viscosity, Increased leads to MCC, Decreased
2444 ASL Height, Decreased leads to Mucus Viscosity, Increased
2513 Increased inflammatory immune responses leads to Heart attack
301 Activation/Proliferation, T-cells leads to N/A, Allergic contact dermatitis on challenge
755 hyperpolarisation, neuron leads to N/A, Ataxia, paralysis, or hyperactivity
1252 Increased, Ductal Hyperplasia leads to N/A, Breast Cancer
1902 Increased pro-inflammatory mediators leads to N/A, Breast Cancer
2576 Increased, Invasion leads to N/A, Breast Cancer
2578 Increase, angiogenesis leads to N/A, Breast Cancer
2579 tumor growth leads to N/A, Breast Cancer
182 N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number leads to N/A, Cyanosis occurs
268 Reduction, Prostaglandin E2 concentration leads to N/A, Gap
172 Activation, Long term AHR receptor driven direct and indirect gene expression changes leads to N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects
995 Changes/Inhibition, Cellular Homeostasis and Apoptosis leads to N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects
592 Respiratory distress/arrest leads to N/A, hypoxia
266 Feminisation or incomplete development, Primary and accessory male sex organs leads to N/A, Impairment of reproductive capacity
287 Binding, SH-/selen-proteins leads to N/A, Interferences with SH-/selen-proteins
82 Accumulation, Collagen leads to N/A, Liver fibrosis
2325 Increased extracellular matrix deposition leads to N/A, Liver fibrosis
2888 Activation, AhR leads to N/A, Liver Steatosis
169 Increase, Liver and splenic hemosiderosis leads to N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number
272 Increase, RBC congestion in liver leads to N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number
278 Damaging, Red blood cells; hemolysis leads to N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number
362 Increased, Intracellular Calcium overload leads to N/A, Mitochondrial dysfunction 1
581 Activation, Nicotinic acetylcholine receptor leads to N/A, Mitochondrial dysfunction 1
912 Increase, ROS production leads to N/A, Mitochondrial dysfunction 1
922 Peptide Oxidation leads to N/A, Mitochondrial dysfunction 1
934 Inhibition, NADH-ubiquinone oxidoreductase (complex I) leads to N/A, Mitochondrial dysfunction 1
993 Disruption, Lysosome leads to N/A, Mitochondrial dysfunction 1
1683 Binding, SH/SeH proteins involved in protection against oxidative stress leads to N/A, Mitochondrial dysfunction 1
1956 Decrease in mitochondrial oxidative phosphorylation leads to N/A, Mitochondrial dysfunction 1
1957 Increased reactive oxygen species (in the mitochondria) leads to N/A, Mitochondrial dysfunction 1
2719 PARP1 leads to N/A, Mitochondrial dysfunction 1
2821 Inhibition, ETC complexes of the respiratory chain leads to N/A, Mitochondrial dysfunction 1
208 Neuroinflammation leads to N/A, Neurodegeneration
364 Cell injury/death leads to N/A, Neurodegeneration
2655 Oxidative Stress in Brain leads to N/A, Neurodegeneration
144 Depletion, GSH leads to N/A, Oxidative stress
123 Reduction, Eggshell thickness leads to N/A, Reproductive failure
649 Decrease, histaminergic neuron excitation leads to N/A, sedation
1693 Increase, cytosolic fatty acid leads to steatohepatitis
1697 increased, oncotic necrosis leads to steatohepatitis
750 Activation, 5HT2c leads to N/A, Unknown
2036 Unknown, MIE leads to N/A, Unknown
2037 test leads to N/A, Unknown
1342 Mitochondrial impairment leads to Necrosis
1830 Cell injury/death leads to Necrotic Tissue
1802 Histone deacetylase inhibition leads to Reduced neural crest cell migration
2562 Disruption, Progenitor cells of second heart field leads to Reduced neural crest cell migration
1808 Altered differentiation leads to Neural tube defects
2699 Histone deacetylase inhibition leads to Neural tube defects
2700 decrease folate leads to Neural tube defects
1733 General Apoptosis leads to Neurodegeneration
1863 Cell injury/death leads to Neurodegeneration
207 N/A, Neurodegeneration leads to Neuroinflammation
210 Neuronal dysfunction leads to Neuroinflammation
365 Cell injury/death leads to Neuroinflammation
656 Synaptogenesis, Decreased leads to Neuroinflammation
907 Degeneration of dopaminergic neurons of the nigrostriatal pathway leads to Neuroinflammation
2286 Binding to ACE2 leads to Neuroinflammation
2507 Accumulation, Toxic Tau oligomers leads to Neuroinflammation
2718 Increase, Cell death leads to Neuroinflammation
2862 Microglia activation leads to Neuroinflammation
215 Inhibition, NMDARs leads to Neuronal dysfunction
239 N/A, Oxidative stress leads to Neuronal dysfunction
2455 Release, Cytokine leads to Neutrophil activation, Increased
2132 Altered, Transcription of genes by AR leads to nipple retention, increased
2133 Antagonism, Androgen receptor leads to nipple retention, increased
2413 Diminished Protective Response to ROS leads to inflammasome activity, increased
2433 TLR9 activation leads to inflammasome activity, increased
1284 TRPA1 activation, TRPA1 Receptor leads to Non-neuronal production of IL-8/CXCL1, Epithelial irritation
1279 SP (Substance P) release, Local increase of SP leads to Non-neuronal production of TNF, Epithelial irritation
883 Decreased, Ketogenesis (production of ketone bodies) leads to Not Increased, Circulating Ketone Bodies
1639 Weak collagen matrix leads to Notochord malformation
1612 increased adipogenesis leads to obesity
1618 decreased DNA methylation of tyrosine hydroxylase leads to obesity
1619 decreased methylation of dopamine transporter promoter leads to obesity
2815 Energy Deposition leads to Cataracts
2816 Modified Proteins leads to Cataracts
2817 Inadequate DNA repair leads to Cataracts
2818 Oxidative Stress leads to Cataracts
2819 Increase, Cell Proliferation leads to Cataracts
2831 ACE2 dysregulation leads to (Micro)vascular dysfunction
684 Generation, Amplified excitatory postsynaptic potential (EPSP) leads to Occurrence, A paroxysmal depolarizing shift
840 Damage, Lipid bilayer leads to Occurrence, Ballooning degeneration (hepatocyte)
844 Disturbance, Lysosomal function leads to Occurrence, Ballooning degeneration (hepatocyte)
848 Injury, Mitochondria leads to Occurrence, Ballooning degeneration (hepatocyte)
2845 Bone Remodeling leads to Bone Loss
2849 Energy Deposition leads to Bone Loss
1140 Increased, blood potassium concentration leads to Occurrence, cardiac arrhythmia
2853 Prolongation of QT interval leads to Occurrence, cardiac arrhythmia
1135 Increased, blood potassium concentration leads to Occurrence, cardiac arrthymia
814 Increased, Serum creatinine leads to Occurrence, Cystic dilatation (renal tubule)
2474 T4 in serum, Decreased leads to Occurrence, Cystic dilatation (renal tubule)
841 Damage, Lipid bilayer leads to Occurrence, Cytoplasmic vacuolization (Bile duct cell)
845 Disturbance, Lysosomal function leads to Occurrence, Cytoplasmic vacuolization (Bile duct cell)
849 Injury, Mitochondria leads to Occurrence, Cytoplasmic vacuolization (Bile duct cell)
839 Damage, Lipid bilayer leads to Occurrence, Cytoplasmic vacuolization (hepatocyte)
843 Disturbance, Lysosomal function leads to Occurrence, Cytoplasmic vacuolization (hepatocyte)
847 Injury, Mitochondria leads to Occurrence, Cytoplasmic vacuolization (hepatocyte)
842 Damage, Lipid bilayer leads to Occurrence, Cytoplasmic vacuolization (kupffer cell)
846 Disturbance, Lysosomal function leads to Occurrence, Cytoplasmic vacuolization (kupffer cell)
850 Injury, Mitochondria leads to Occurrence, Cytoplasmic vacuolization (kupffer cell)
816 Increased, Serum creatinine leads to Occurrence, Cytoplasmic vacuolization (podocyte)
2475 T4 in serum, Decreased leads to Occurrence, Cytoplasmic vacuolization (podocyte)
813 Increased, Serum creatinine leads to Occurrence, Cytoplasmic vacuolization (Renal tubule)
2473 T4 in serum, Decreased leads to Occurrence, Cytoplasmic vacuolization (Renal tubule)
630 Occurrence, A paroxysmal depolarizing shift leads to Occurrence, Epileptic seizure
1860 Increased, Intracellular Calcium overload leads to Occurrence, Epileptic seizure
1889 Activation, Muscarinic Acetylcholine Receptors leads to Occurrence, Focal Seizure
944 Increased goblet cell proliferation leads to Goblet cell hyperplasia
829 Decreased, Glomerular filtration leads to Occurrence, Kidney toxicity
830 Decreased, Renal plasma flow leads to Occurrence, Kidney toxicity
831 Decreased, Sodium reabsorption leads to Occurrence, Kidney toxicity
832 Decreased, Renal ability to dilute urine leads to Occurrence, Kidney toxicity
1676 Increase, Cytotoxicity (renal tubular cell) leads to Occurrence, Kidney toxicity
2647 Occurrence, renal proximal tubular necrosis leads to Occurrence, Kidney toxicity
943 Occurrence, Transdifferentiation of ciliated epithelial cells leads to Goblet cell metaplasia
2469 Activation, EGFR leads to Goblet cell metaplasia
2470 Decreased ciliated cell apoptosis leads to Goblet cell metaplasia
1138 Decreased, Prostaglandin F2alpha concentration, plasma leads to Occurrence, renal ischemia
1133 Occurrence, tophi (urate) deposition leads to Occurrence, renal proximal tubular necrosis
1139 Occurrence, renal ischemia leads to Occurrence, renal proximal tubular necrosis
1160 Increased, Oxidative Stress leads to Occurrence, renal proximal tubular necrosis
2645 Increase, Apoptosis leads to Occurrence, renal proximal tubular necrosis
2646 Increase in inflammation leads to Occurrence, renal proximal tubular necrosis
1132 Increased, blood uric acid concentration leads to Occurrence, tophi (urate) deposition
942 Activation, Epidermal Growth Factor Receptor leads to Occurrence, Transdifferentiation of ciliated epithelial cells
961 Decreased ciliated cell apoptosis leads to Occurrence, Transdifferentiation of ciliated epithelial cells
965 Activation, EGFR leads to Occurrence, Transdifferentiation of ciliated epithelial cells
2784 Increase, Endothelial Dysfunction leads to Occurrence, Vascular Remodeling
2785 Energy Deposition leads to Occurrence, Vascular Remodeling
2363 olfacotry neurons, decrease leads to Olfactory epithelium degeneration
2362 Sustentacular cells, decrease leads to olfacotry neurons, decrease
1271 TRPA1 activation, TRPA1 Receptor leads to Opening of calcium channel, Calcium influx
1281 TRPV1 activation, TRPV1 leads to Opening of calcium channel, Calcium influx
1287 Non-neuronal production of IL-8/CXCL1, Epithelial irritation leads to Opening of calcium channel, Calcium influx
1288 Non-neuronal production of TNF, Epithelial irritation leads to Opening of calcium channel, Calcium influx
1564 Release of G Proteins leads to Opening of GIRK channels
2726 Decrease, outgrowth leads to OFC
2894 Antagonism Smoothened leads to OFC
1196 Uncarboxylated osteocalcin not incorporated into bone matrix, decreasing bone strength, Imp leads to Osteoporosis and vascular calcification, Bone deterioration
605 Overactivation, Neuronotransmitter release leads to Overactivation, muscle contraction
604 prolonged, Depolarization of neuronal membrane leads to Overactivation, Neuronotransmitter release
360 Binding of agonist, NMDARs leads to Overactivation, NMDARs
919 Binding of agonist, Ionotropic glutamate receptors leads to Overactivation, NMDARs
1859 Increased, glutamate leads to Overactivation, NMDARs
1998 Occurrence, Focal Seizure leads to Overactivation, NMDARs
1999 Occurrence, Epileptic seizure leads to Overactivation, NMDARs
2141 Status epilepticus leads to Overactivation, NMDARs
2403 Inhibition of Plxna2 leads to Overexpression of rasl11b
660 N/A, Mitochondrial dysfunction 1 leads to Overwhelmed, Mitochondrial DNA repair mechanisms
1847 ROS generation leads to Oxidation of DNA
1845 ROS generation leads to Oxidation of membrane lipids
948 Peptide Oxidation leads to Oxidation, Glutathione
867 Inhibition, UROD leads to Oxidation, Uroporphyrinogen
868 Induction, CYP1A2/CYP1A5 leads to Oxidation, Uroporphyrinogen
1846 ROS generation leads to Oxidation/denatuation of membrane proteins
1512 Activation of Cyp2E1 leads to Oxidative Stress
1684 N/A, Mitochondrial dysfunction 1 leads to Oxidative Stress
1689 Binding, SH/SeH proteins involved in protection against oxidative stress leads to Oxidative Stress
1766 Protection against oxidative stress, decreased leads to Oxidative Stress
2009 Increased, Reactive oxygen species leads to Oxidative Stress
2291 SARS-CoV-2 production leads to Oxidative Stress
2313 Coagulation leads to Oxidative Stress
2499 Mitochondrial dysfunction leads to Oxidative Stress
2668 Non-coding RNA expression,alteration leads to Oxidative Stress
2713 Decrease, OXPHOS leads to Oxidative Stress
2769 Energy Deposition leads to Oxidative Stress
2826 Increase, ROS leads to Oxidative Stress
1726 CYP2E1 Activation leads to Oxidative Stress in Brain
2654 Activation of Cyp2E1 leads to Oxidative Stress in Brain
1710 Histone acetylation, increase leads to p21 (CDKN1A) expression, increase
1714 Histone deacetylase inhibition leads to p21 (CDKN1A) expression, increase
2032 Acinar cell proliferation leads to Acinar cell tumors
910 Degeneration of dopaminergic neurons of the nigrostriatal pathway leads to Parkinsonian motor deficits
2706 Increase, Cell death leads to Parkinsonian motor deficits
96 Up Regulation, CYP1A1 leads to Peptide Oxidation
146 Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells) leads to Peptide Oxidation
271 Alkylation, Protein leads to Peptide Oxidation
276 Production, Reactive oxygen species leads to Peptide Oxidation
763 Increase, Oxidative metabolism leads to Peptide Oxidation
921 Disruption, Lysosome leads to Peptide Oxidation
1234 Increase, Genes involved in fatty acid oxidation leads to Peptide Oxidation
1235 Activation, NADPH Oxidase leads to Peptide Oxidation
1241 Increase, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids leads to Peptide Oxidation
1466 Increase, ROS leads to Peptide Oxidation
2515 Altered mechanotransduction properties of pericytes leads to Pericyte dysfunction
477 Suppression, Constitutive androstane receptor, NR1l3 leads to demethylation, PPARg promoter
1423 Activation, L-FABP leads to demethylation, PPARg promoter
1372 Up Regulation, Unsaturated fatty acid leads to Perturbation of cholesterol
1375 Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene leads to Perturbation of cholesterol
2150 Activation, JNK leads to Pin-1 activation
2454 Release, Cytokine leads to Platelet activation, Increased
2456 Platelet activation, Increased leads to Platelet-neutrophil interactions, Increased
2457 Neutrophil activation, Increased leads to Platelet-neutrophil interactions, Increased
2069 Chronic ROS leads to Porcupine-induced Wnt secretion and Wnt signaling activation
2526 Increases in cellular ROS leads to Porcupine-induced Wnt secretion and Wnt signaling activation
2606 Activation of TP53 leads to Premature differentiation
2527 increased atRA concentration leads to premature meiosis, male germ cells
1187 Increase, cilia movement leads to premature, Spawning
1210 Increased, cilia movement leads to premature, Spawning
1225 Increased, water pumping leads to premature, Spawning
1178 Increase, cilia movement leads to premature, spawning 1
1286 Oxidization of biomolecules, Lipid bilayer and cellular proteins leads to Production of nerve growth factor , Epithelial irritation
1293 Oxidation leads to Production of nerve growth factor , Epithelial irritation
1356 Differentiation of Myofibroblast leads to Production of α-smooth muscle actin
930 Bile accumulation, Pathological condition leads to Production, Reactive oxygen species
324 N/A, Unknown leads to Proliferation, Cell proliferation in the absence of cytotoxicity
1104 Promotion, SIX-1 postive basal-type progenitor cells leads to Proliferation/Clonal Expansion, aberrant basal cells
1081 relaxation, smooth muscle leads to Proliferation/Clonal Expansion, smooth muscle
2539 Inhibition of Ikr leads to Prolongation of Action Potential
2851 Inhibition of rapid delayed rectifying potassium current leads to Prolongation of Action Potential
2540 Prolongation of Action Potential leads to Prolongation of QT interval
603 modulation, sodium channel leads to prolonged, Depolarization of neuronal membrane
1100 Increased, cholestasis leads to prolonged, elevation of serun CCK
1110 Decreased, LH Surge from anterior pituitary leads to prolonged, estrus
158 Hyperplasia, Hyperplasia leads to Promotion, Hepatocelluar carcinoma
1083 Hypertrophy/hyperplasia, smooth muscle leads to Promotion, mesovarian leiomyomas
1093 Hyperplasia, ovarian epithelium leads to Promotion, ovarian adenomas
2829 Promotion, ovarian adenomas leads to Promotion, Ovarian Cancer
2830 Promotion, ovarian granular cell tumors leads to Promotion, Ovarian Cancer
1094 Hyperplasia, ovarian stromal cells leads to Promotion, ovarian granular cell tumors
1103 Activation, estrogen receptor alpha leads to Promotion, SIX-1 postive basal-type progenitor cells
244 N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin leads to Propagation, Oxidative stress
1836 Interaction of α-diketones with arginine residues leads to Proteasomal dysfunction
1728 Lipid Peroxidation leads to Protein Adduct Formation
2019 Th17 cell migration and inflammation induction leads to Skin disease
1629 Accumulation, Collagen leads to Pulmonary fibrosis
1708 Increased extracellular matrix deposition leads to Pulmonary fibrosis
2154 EMT leads to Pulmonary fibrosis
2673 Activation, inflammation pathway leads to Pulmonary inflammation
2674 Oxidative Stress leads to Pulmonary inflammation
1844 Absorption of photon energy leads to Radical generation
1446 Inactivated, 5-HTR leads to Reduce expression, BDNF
2075 Increase, Apoptosis leads to Reduce, Sperm count
2694 Inhibition CerS leads to Reduced complex sphingolipids
973 dimerization, AHR/ARNT leads to reduced dimerization, ARNT/HIF1-alpha
1170 Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tis leads to Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction
347 Decreased, Calcium influx leads to BDNF, Reduced
444 T4 in neuronal tissue, Decreased leads to BDNF, Reduced
1504 TH synthesis, Decreased leads to BDNF, Reduced
974 reduced dimerization, ARNT/HIF1-alpha leads to reduced production, VEGF
2481 Oocyte meiosis, disrupted leads to Ovarian follicle pool, reduced
1974 Alveolar collapse leads to Reduced tidal volume
2256 Inhibition of LS function. leads to Reduced tidal volume
2369 Loss of alveolar capillary membrane integrity leads to Reduced tidal volume
673 Reduced, Spawning behavior leads to Reduced, Ability to attract spawning mates
679 Reduced, Pheromone release leads to Reduced, Ability to attract spawning mates
1031 Reduced, Posterior swim bladder inflation leads to Reduced, Anterior swim bladder inflation
1035 Decreased, Triiodothyronine (T3) leads to Reduced, Anterior swim bladder inflation
1039 T4 in serum, Decreased leads to Reduced, Anterior swim bladder inflation
1040 Thyroperoxidase, Inhibition leads to Reduced, Anterior swim bladder inflation
1043 Inhibition, Deiodinase 2 leads to Reduced, Anterior swim bladder inflation
1045 Inhibition, Deiodinase 1 leads to Reduced, Anterior swim bladder inflation
577 Decreased, Hydrogen peroxide production leads to Reduced, Antiseptic incorporated in food
1451 Activation, Glucocorticoid Receptor leads to Reduced, BDNF
1511 Inactivated, 5-HTR leads to Reduced, BDNF
1522 Increased, glucocorticoid receptor activity leads to Reduced, BDNF
565 Abnormal, Roll change within caste leads to Reduced, Brood care
1561 Reduced, HSD17B4 activity leads to Reduced, fatty acid beta oxidation
587 Reduced, swimming speed leads to Reduced, feeding 1
579 Abnormal, Roll change within caste leads to Reduced, Food storage
584 Abnormal, Foraging activity and behavior leads to Reduced, Food storage
1556 NFE2/Nrf2 repression leads to Reduced, FXR activity
1552 Decreased, GABA leads to Reduced, GABA-A receptor activation
1555 Increased, RDX dose leads to Reduced, GABA-A receptor activation
690 Reduced, Prostaglandin E2 concentration, hypothalamus leads to Reduced, Gonadotropin releasing hormone, hypothalamus
1032 Reduced, Anterior swim bladder inflation leads to Reduced, Hearing
2468 Altered, inner ear development leads to Reduced, Hearing
1560 Reduced, PPARalpha leads to Reduced, HSD17B4 activity
691 Reduced, Gonadotropin releasing hormone, hypothalamus leads to Reduced, Luteinizing hormone (LH), plasma
693 Reduced, Maturation inducing steroid, plasma leads to Reduced, Maturation inducing steroid receptor signalling, oocyte
692 Reduced, Luteinizing hormone (LH), plasma leads to Reduced, Maturation inducing steroid, plasma
696 Increased, cyclic adenosine monophosphate leads to Reduced, Meiotic prophase I/metaphase I transition, oocyte
1535 Decreased, mucosal blood flow leads to Reduced, mucosal defense
1538 Decreased, mucous leads to Reduced, mucosal defense
1540 Decreased, bicarbonate leads to Reduced, mucosal defense
1547 Decrease, surfactant leads to Reduced, mucosal defense
678 Reduced, Prostaglandin F2alpha concentration, plasma leads to Reduced, Pheromone release
1532 Reduced, PTGS1 function leads to Reduced, platelet aggregation
1027 Decreased, Triiodothyronine (T3) leads to Reduced, Posterior swim bladder inflation
1042 Inhibition, Deiodinase 2 leads to Reduced, Posterior swim bladder inflation
1044 Inhibition, Deiodinase 1 leads to Reduced, Posterior swim bladder inflation
1559 Activated, LXR leads to Reduced, PPARalpha
354 BDNF, Reduced leads to Reduced, Presynaptic release of glutamate
689 Inhibition, Cyclooxygenase activity leads to Reduced, Prostaglandin E2 concentration, hypothalamus
671 Reduced, Prostaglandin F2alpha synthesis, ovary leads to Reduced, Prostaglandin F2alpha concentration, plasma
682 Decreased, Prostaglandin F2alpha synthesis, ovary leads to Reduced, Prostaglandin F2alpha concentration, plasma
670 Inhibition, Cyclooxygenase activity leads to Reduced, Prostaglandin F2alpha synthesis, ovary
686 Inhibition, Cyclooxygenase activity leads to Reduced, Prostaglandins, ovary
674 Reduced, Ability to attract spawning mates leads to Reduced, Reproductive Success
687 Decrease, Ovulation leads to Reduced, Reproductive Success
695 Increased, cyclic adenosine monophosphate leads to Reduced, Reproductive Success
697 Reduced, Meiotic prophase I/metaphase I transition, oocyte leads to Reduced, Reproductive Success
700 Increased, Chromosome misseggregation leads to Reduced, Reproductive Success
1557 Reduced, FXR activity leads to Reduced, SHP activity
672 Reduced, Prostaglandin F2alpha concentration, plasma leads to Reduced, Spawning behavior
595 Increased, predation leads to Reduced, survival
596 Reduced, feeding 1 leads to Reduced, survival
1028 Reduced, Posterior swim bladder inflation leads to Reduced, Swimming performance
1034 Reduced, Anterior swim bladder inflation leads to Reduced, Swimming performance
1640 Notochord malformation leads to Reduced, Swimming performance
2080 Inhibition, Fin regeneration leads to Reduced, Swimming performance
586 Decreased, Sodium conductance 1 leads to Reduced, swimming speed
1894 Reduction of melanosome level leads to Reduction fo Pigmentation pattern
1892 Reduction of L-Dopaquinone leads to Reduction in melanin level
395 demethylation, PPARg promoter leads to reduction in ovarian granulosa cells, Aromatase (Cyp19a1)
1637 Inhibition of lysyl oxidase leads to Reduction of collagen crosslinking
1891 tyrosinase leads to Reduction of L-Dopaquinone
1893 Reduction in melanin level leads to Reduction of melanosome level
1878 Inhibition of Cyp17A1 activity leads to Reduction, DHEA
1879 Inhibition of Cyp17A1 activity leads to Reduction, androstenedione
43 Decrease, Aromatase (Cyp19a1) leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
45 Inhibition, Aromatase leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
104 Up Regulation, CYP1B1 leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
302 Reduction, Testosterone synthesis by ovarian theca cells leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
396 reduction in ovarian granulosa cells, Aromatase (Cyp19a1) leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
801 Decreased, Aromatase (Cyp19a1) mRNA leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
1384 Agonism, Androgen receptor leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
1995 Decease, expression of GnRHR leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
2144 Inhibition, Aromatase leads to Reduction, E2 Synthesis by the undifferentiated gonad
335 Inhibition, VegfR2 leads to Reduction, Angiogenesis
136 N/A, Gap leads to Reduction, Ca and HCO3 transport to shell gland
436 Decrease, Steroidogenic acute regulatory protein (STAR) leads to Reduction, Cholesterol transport in mitochondria
437 Decrease, Translocator protein (TSPO) leads to Reduction, Cholesterol transport in mitochondria
337 Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development leads to Reduction, Cumulative fecundity and spawning
544 Decrease, Ovulation leads to Reduction, Cumulative fecundity and spawning
1769 Reduction, Plasma vitellogenin concentrations leads to Reduction, Cumulative fecundity and spawning
2588 Decrease, Oogenesis leads to Reduction, Cumulative fecundity and spawning
1882 Reduction, Plasma vitellogenin concentrations leads to Reduction, egg production and spawning
59 Reduction, Ca and HCO3 transport to shell gland leads to Reduction, Eggshell thickness
31 Agonism, Androgen receptor leads to Reduction, Gonadotropins, circulating concentrations
666 Binding at picrotoxin site, iGABAR chloride channel leads to Reduction, Ionotropic GABA receptor chloride channel conductance
667 Reduction, Ionotropic GABA receptor chloride channel conductance leads to Reduction, Neuronal synaptic inhibition
1017 Interference, nuclear localization of NFAT leads to Reduction, NFAT/AP-1 complex formation
5 Reduction, 17beta-estradiol synthesis by ovarian granulosa cells leads to Reduction, Plasma 17beta-estradiol concentrations
1768 TH synthesis, Decreased leads to Reduction, Plasma 17beta-estradiol concentrations
1881 Decrease, DHT level leads to Reduction, Plasma 17beta-estradiol concentrations
1987 Reduction, Progesterone synthesis leads to Reduction, Plasma progesterone concentration
315 Reduction, Vitellogenin synthesis in liver leads to Reduction, Plasma vitellogenin concentrations
1386 Reduction, Plasma 17beta-estradiol concentrations leads to Reduction, Plasma vitellogenin concentrations
1986 Antagonism,LH receptor leads to Reduction, Progesterone synthesis
1988 Reduction, Plasma progesterone concentration leads to Reduction, progesterone uptake, decresed maturation
95 Inhibition, Cyclooxygenase activity leads to Reduction, Prostaglandin E2 concentration
439 Reduction, Testosterone synthesis in Leydig cells leads to Reduction, testosterone level
2125 Reduction, Testosterone synthesis in Leydig cells leads to reduction, testosterone levels
32 Agonism, Androgen receptor leads to Reduction, Testosterone synthesis by ovarian theca cells
143 Reduction, Gonadotropins, circulating concentrations leads to Reduction, Testosterone synthesis by ovarian theca cells
399 Decrease, Translocator protein (TSPO) leads to Reduction, Testosterone synthesis in Leydig cells
438 Reduction, Cholesterol transport in mitochondria leads to Reduction, Testosterone synthesis in Leydig cells
1647 Increased apoptosis, decreased Leydig Cells leads to Reduction, Testosterone synthesis in Leydig cells
1648 Repressed expression of steroidogenic enzymes leads to Reduction, Testosterone synthesis in Leydig cells
253 Reduction, Plasma 17beta-estradiol concentrations leads to Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
255 Reduction, Plasma vitellogenin concentrations leads to Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
129 Antagonism, Estrogen receptor leads to Reduction, Vitellogenin synthesis in liver
252 Reduction, Plasma 17beta-estradiol concentrations leads to Reduction, Vitellogenin synthesis in liver
1385 Agonism, Androgen receptor leads to Reduction, Vitellogenin synthesis in liver
1080 Increased activity, beta-2 adrenergic receptor leads to relaxation, smooth muscle
1563 Mu Opioid Receptor Agonism leads to Release of G Proteins
1571 Serotonin 1A Receptor Agonism leads to Release of G Proteins
923 Peptide Oxidation leads to Release, Cytokine
924 Cell injury/death leads to Release, Cytokine
928 Bile accumulation, Pathological condition leads to Release, Cytokine
1962 Frustrated phagocytosis leads to Release, Cytokine
2431 Increase activation, Nuclear factor kappa B (NF-kB) leads to Release, Cytokine
2453 Endothelial cell dysfunction leads to Release, Cytokine
1021 Reduction, NFAT/AP-1 complex formation leads to Relief, Relief of atopic dermatitis
1646 GR Agonist, Activation leads to Repressed expression of steroidogenic enzymes
2485 GSK3beta inactivation leads to Repression of Gbx2 expression
1368 Apoptosis leads to Reproductive failure
1370 Activation, TGF-beta pathway leads to Reproductive failure
1383 Defect of Embryogenesis leads to Reproductive failure
450 AchE Inhibition leads to Respiratory distress/arrest
457 Increased Cholinergic Signaling leads to Respiratory distress/arrest
591 Increased, Atrioventricular block and bradycardia leads to Respiratory distress/arrest
2006 Cardiovascular dysregulation leads to Respiratory distress/arrest
376 Covalent Binding, Protein leads to Response, Keratinocytes
1360 Activation, NADPH Oxidase leads to ROS formation
1843 Absorption of photon energy leads to ROS generation
2056 Binding to ACE2 leads to SARS-CoV-2 cell entry
2509 Upregulation of ACE2 leads to SARS-CoV-2 cell entry
1856 Eczematous eruption leads to Scaling, Lichenification
2660 Increased, Reactive oxygen species leads to Secondary genotoxicity
2664 Increase, Cytotoxicity (epithelial cells) leads to Secondary genotoxicity
835 Activation/Proliferation, T-cells leads to sensitisation, skin
1289 Generation of novel epitopes , Antigen presentation leads to Sensitization, Immune system
1290 Leukocyte infiltration leads to Sensitization, Immune system
1835 Impaired axonial transport leads to Sensory axonal peripheral neuropathy
2656 Decreased, Neuronal network function in adult brain leads to Sensory axonal peripheral neuropathy
1498 7α-hydroxypregnenolone synthesis in the brain, decreased leads to Sexual behavior, decreased
1502 Dopamine release in the brain, decreased leads to Sexual behavior, decreased
2437 foxi1 expression, increased leads to six1b expression, increased
1927 β-catenin activation leads to Snail, Zeb, Twist activation
1280 Opening of calcium channel, Calcium influx leads to SP (Substance P) release, Local increase of SP
1283 Production of nerve growth factor , Epithelial irritation leads to SP (Substance P) release, Local increase of SP
1575 Excitation, Trigeminal nerve excitation leads to SP (Substance P) release, Local increase of SP
1735 Apoptosis leads to Spermatocyte depletion
2010 Histone deacetylase inhibition leads to Spermatocyte depletion
1105 Proliferation/Clonal Expansion, aberrant basal cells leads to squamous metaplasia, aberrant basal cells
1023 Binding of antagonist, PPAR alpha leads to stabilization, PPAR alpha co-repressor
2140 Increased, Intracellular Calcium overload leads to Status epilepticus
2781 Overactivation, NMDARs leads to Status epilepticus
2259 Loss of alveolar capillary membrane integrity leads to Substance - LS interaction
2542 Torsades de Pointes leads to Sudden cardiac death
2866 SDH, inhibited leads to Superoxide generation, increased
1815 Impaired IL-1 signaling leads to Suppressed AP-1
1817 Suppressed AP-1 leads to Suppressed DC activation
1818 Suppressed NF-kB leads to Suppressed DC activation
1824 Decreased IL-1 production leads to Suppressed MyD88
1825 Impaired IL-1 signaling leads to Suppressed MyD88
1816 Impaired IL-1 signaling leads to Suppressed NF-kB
2000 Impaired IL-1R1 signaling leads to Suppression of T cell activation
2003 Inhibition, Nuclear factor kappa B (NF-kB) leads to Suppression of T cell activation
2026 Suppression of STAT5 binding to cytokine gene promoters leads to Suppression of IL-4 production
2025 STAT5 inhibition leads to Suppression of STAT5 binding to cytokine gene promoters
1254 Inhibition, Calcineurin Activity leads to Suppression, IL-2 and IL-4 production
1509 Reduction, NFAT/AP-1 complex formation leads to Suppression, IL-2 and IL-4 production
390 Decreased, Lymphocytes leads to Suppression, Immune system
387 Inhibition, Nuclear factor kappa B (NF-kB) leads to Suppression, Inflammatory cytokines
1018 Reduction, NFAT/AP-1 complex formation leads to Suppression, Suppression in mixed lymphocyte reaction (MLR)
1256 Reduction, NFAT/AP-1 complex formation leads to Suppression, Suppression of production of cytotoxic T-cells
1257 Reduction, NFAT/AP-1 complex formation leads to Suppression, Suppression of T-cell dependent antibody production
1019 Reduction, NFAT/AP-1 complex formation leads to Suppression, Suppression of T-cell dependent antibody response (TDAR)
1821 Impaired T cell activation leads to Suppression, Suppression of T-cell dependent antibody response (TDAR)
509 Activation, AhR leads to Suppression, VLDL secretion
2361 SARS-CoV-2 cell entry leads to Sustentacular cells, decrease
2545 SARS-CoV-2 production leads to Sustentacular cells, decrease
2506 Impaired axonial transport leads to Dysfunctional synapses
2807 Loss of drebrin leads to Dysfunctional synapses
77 Activation, ChREBP leads to Synthesis, De Novo FA
133 Activation, FAS leads to Synthesis, De Novo FA
284 Activation, SCD-1 leads to Synthesis, De Novo FA
294 Activation, SREBP-1c leads to Synthesis, De Novo FA
1589 Increased expression of APP leads to Systemic APR
1713 Apoptosis leads to Testicular atrophy
1717 Histone deacetylase inhibition leads to Testicular atrophy
1734 Spermatocyte depletion leads to Testicular atrophy
2018 Increase of IL-23 leads to Th17 cell migration and inflammation induction
2458 Platelet-neutrophil interactions, Increased leads to Thromboinflammation, Increased
2290 Coagulation leads to Thrombosis and DIC
309 Thyroperoxidase, Inhibition leads to TH synthesis, Decreased
552 Inhibition, Na+/I- symporter (NIS) leads to TH synthesis, Decreased
872 Thyroidal Iodide, Decreased leads to TH synthesis, Decreased
1202 Inhibition, Pendrin leads to TH synthesis, Decreased
1203 Inhibition, Dual oxidase leads to TH synthesis, Decreased
2421 Decreased, Uptake of inorganic iodide leads to TH synthesis, Decreased
2897 Increase, Oxidative Stress leads to TH synthesis, Decreased
312 T4 in serum, Decreased leads to T4 in neuronal tissue, Decreased
1718 Cell injury/death leads to Tissue resident cell activation
1898 Increase, DNA Damage leads to Tissue resident cell activation
1906 Increase in RONS leads to Tissue resident cell activation
2832 Energy Deposition leads to Tissue resident cell activation
2833 Oxidative Stress leads to Tissue resident cell activation
2302 SARS-CoV-2 cell entry leads to TLR Activation/Dysregulation
2316 Increased viral transcription and replication leads to TLR Activation/Dysregulation
2351 SARS-CoV-2 production leads to TLR Activation/Dysregulation
2541 Prolongation of QT interval leads to Torsades de Pointes
2563 Reduced neural crest cell migration leads to Transposition of the great arteries
1929 Epithelial-mesenchymal transition leads to Resistant gastric cancer
1276 Excitation, Trigeminal nerve excitation leads to Increased Airway Hyper-responsiveness,Cough, Dyspnea
1574 SP (Substance P) release, Local increase of SP leads to Increased Airway Hyper-responsiveness,Cough, Dyspnea
1579 Increased CGRP leads to Increased Airway Hyper-responsiveness,Cough, Dyspnea
1584 Increased NKA leads to Increased Airway Hyper-responsiveness,Cough, Dyspnea
1770 Respiratory irritability leads to Increased Airway Hyper-responsiveness,Cough, Dyspnea
1774 Irritation induced sneezing leads to Increased Airway Hyper-responsiveness,Cough, Dyspnea
1274 Opening of calcium channel, Calcium influx leads to Excitation, Trigeminal nerve excitation
1282 Oxidization of biomolecules, Lipid bilayer and cellular proteins leads to TRPA1 activation, TRPA1 Receptor
1292 Oxidation leads to TRPA1 activation, TRPA1 Receptor
343 Increased, Proliferation/Clonal Expansion of Mutant Cells (Pre-Neoplastic Lesions/Altered H leads to Tumorigenesis, Hepatocellular carcinoma
345 Formation, Pro-mutagenic DNA Adducts leads to Tumorigenesis, Hepatocellular carcinoma
346 Increased, Induced Mutations in Critical Genes leads to Tumorigenesis, Hepatocellular carcinoma
350 Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci leads to Tumorigenesis, Hepatocellular carcinoma
550 Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF) leads to Tumorigenesis, Hepatocellular carcinoma
1195 Calcium cannot bind to the hydroxyapatite matrix of bone, Osteocalcin and other bone protei leads to Uncarboxylated osteocalcin not incorporated into bone matrix, decreasing bone strength, Imp
1166 Hemostasis, Depletion from blood of fully functional carboxylated clotting factors leads to Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failur
1729 Protein Adduct Formation leads to Unfolded Prortein Response
1730 Oxidative Stress in Brain leads to Unfolded Prortein Response
1865 Accumulation, misfolded proteins leads to Unfolded Prortein Response
2711 Endoplasmic reticulum stress leads to Unfolded Prortein Response
2035 Unknown, MIE leads to Unknown,
2034 test leads to Unknown, MIE
516 Activation, LXR leads to Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)
173 Activation, LXR leads to Up Regulation, CD36
411 demethylation, PPARg promoter leads to Up Regulation, CD36
495 Activation, AhR leads to Up Regulation, CD36
529 Activation, PXR/SXR leads to Up Regulation, CD36
2261 Activation, Glucocorticoid Receptor leads to Up Regulation, CD36
17 Altered expression of AHR/ARNT pathway-dependent genes leads to Up Regulation, CYP1A1
19 Activation, AhR leads to Up Regulation, CYP1A1
490 Activation, LXR leads to Up Regulation, FAS
506 Activation, AhR leads to Up Regulation, LDLR (low density lipoprotein receptor)
489 Activation, SREBF1 leads to Up Regulation, SCD-1
491 Activation, LXR leads to Up Regulation, SCD-1
526 Activation, PXR/SXR leads to Up Regulation, SCD-1
1656 Activation, AhR leads to Up Regulation, SCD-1
147 Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells) leads to Up Regulation, TGFbeta1 expression
1371 Up Regulation, SREBF2 leads to Up Regulation, Unsaturated fatty acid
698 Reduced, Maturation inducing steroid receptor signalling, oocyte leads to Upregulated, Spindle assembly checkpoint protein Mad2-oocyte
866 Accumulation, Highly carboxylated porphyrins leads to Uroporphyria
2083 Mitochondrial impairment leads to cell injury
2085 Increase, Hyperplasia (urothelial) leads to carcinogenicity
2770 Energy Deposition leads to Vascular remodeling
2778 Increase, Endothelial Dysfunction leads to Vascular remodeling
2692 Impaired, Spermatogenesis leads to Viable offspring, decreased
2498 SARS-CoV-2 production leads to Viral infection, proliferated
1638 Reduction of collagen crosslinking leads to Weak collagen matrix
2755 Decrease, Chitin laminar organization leads to Weak, Procuticle protection
2756 Decrease, Prevent chitin degradation by chitinases leads to Weak, Procuticle protection
1144 Abnormal, Foraging activity and behavior leads to Weakened, Colony
1149 Abnormal, Roll change within caste leads to Weakened, Colony
1151 Abnormal, Role change within caste leads to Weakened, Colony
1153 impaired, Hive thermoregulation leads to Weakened, Colony
1154 N/A, Mitochondrial dysfunction 1 leads to Weakened, Colony
1155 Increased, Deformed Wing Virus levels leads to Weakened, Colony
2008 Oxidative Stress leads to Wnt ligand stimulation
1926 GSK3beta inactivation leads to β-catenin activation
2033 Increased, Reactive oxygen species leads to β-catenin activation